Prevention and treatment of tuberculosis

Abstract

Provided is a compound for preventing or treating tuberculosis (TB) or an acceptable salt thereof, the compound being represented by general formula (I).

Description

Tuberculosis prevention and treatment

[0001] Citation of Related Applications

[0002] This disclosure claims all rights and interests in the Chinese invention patent application with application number 202410339933.7 and invention name “Prevention and Treatment of Tuberculosis” filed with the State Intellectual Property Office of the People’s Republic of China on March 22, 2024, and incorporates its contents into this disclosure in their entirety by reference.

[0003] field

[0004] The present disclosure relates generally to the field of biomedicine, and more particularly to the prevention and treatment of tuberculosis.

[0005] background

[0006] Tuberculosis (TB) is caused by infection with Mycobacterium tuberculosis (MTB). M. tuberculosis can invade various host organs, with the lungs being the most common. Latent tuberculosis infection (LTBI) is a specific condition in which a host is infected with M. tuberculosis but has not yet developed symptoms, with no clinical manifestations, imaging changes, or bacteriological evidence of active TB. If left untreated, approximately 5% to 10% of individuals with latent TB infection will develop active TB.

[0007] Overview

[0008] In one aspect, the present disclosure relates to a method for preventing or treating tuberculosis (TB), comprising administering to an individual in need thereof a preventive or therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof,

[0009] in

[0010] R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0011] R3 is selected from an optionally substituted amino group;

[0012] R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0013] R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy;

[0014] R6 is selected from a chemical bond or an optionally substituted alkylene group;

[0015] R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and

[0016] X is selected from CH or N.

[0017] In another aspect, the present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for preventing or treating tuberculosis (TB).

[0018] in

[0019] R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0020] R3 is selected from an optionally substituted amino group;

[0021] R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0022] R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy;

[0023] R6 is selected from a chemical bond or an optionally substituted alkylene group;

[0024] R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and

[0025] X is selected from CH or N.

[0026] In another aspect, the present disclosure relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing or treating tuberculosis (TB).

[0027] in

[0028] R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0029] R3 is selected from an optionally substituted amino group;

[0030] R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0031] R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy;

[0032] R6 is selected from a chemical bond or an optionally substituted alkylene group;

[0033] R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and

[0034] X is selected from CH or N.

[0035] In another aspect, the present disclosure relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in preventing or treating tuberculosis (TB).

[0036] in

[0037] R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0038] R3 is selected from an optionally substituted amino group;

[0039] R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0040] R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy;

[0041] R6 is selected from a chemical bond or an optionally substituted alkylene group;

[0042] R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and

[0043] X is selected from CH or N.

[0044] On the other hand, the present disclosure relates to a pharmaceutical composition for preventing or treating tuberculosis (TB), comprising a preventive or therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0045] in

[0046] R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0047] R3 is selected from an optionally substituted amino group;

[0048] R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0049] R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy;

[0050] R6 is selected from a chemical bond or an optionally substituted alkylene group;

[0051] R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and

[0052] X is selected from CH or N.

[0053] Details

[0054] In the following description, certain specific details are included to provide a thorough understanding of each disclosed embodiment. However, one skilled in the relevant art will recognize that the embodiments can be implemented without one or more of these specific details and with other methods, components, materials, etc.

[0055] Unless otherwise required by this disclosure, throughout this specification and the claims that follow, the words "include" and "comprising" should be construed in an open, inclusive sense, ie, "including, but not limited to."

[0056] Reference throughout this specification to "one embodiment" or "another embodiment" or "an embodiment" or "certain embodiments" means that the particular referenced elements, structures, or features described in connection with that embodiment are included in at least one embodiment. Thus, appearances of the phrases "one embodiment" or "an embodiment" or "another embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular elements, structures, or features may be combined in any suitable manner in one or more embodiments.

[0057] It should be understood that the singular article "a", "an" and "the" used in the specification of the present disclosure and the appended claims include plural objects unless the context clearly provides otherwise. Therefore, for example, a pharmaceutical composition comprising "a compound of formula (I) or a pharmaceutically acceptable salt thereof" includes one compound of formula (I) or a pharmaceutically acceptable salt thereof, or two or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.

[0058] definition

[0059] Accordingly, unless otherwise indicated to the contrary, the following terms used in the specification and appended claims shall have the following meanings:

[0060] Certain chemical groups named in this disclosure are preceded by abbreviations indicating the total number of carbon atoms present in the indicated chemical group. For example, C1-C4 alkyl describes an alkyl group as defined below having a total of 1 to 4 carbon atoms, while C3-C4 alkyl describes an alkyl group ... 10 Cycloalkyl describes a cycloalkyl group as defined below having a total of 3 to 10 carbon atoms. The total number of carbons in the shorthand notation does not include carbons that may be present in substituents of the group being described.

[0061] In this disclosure, the term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0062] In this disclosure, the term "hydroxyl" refers to an -OH group.

[0063] In this disclosure, the term "amino" refers to a -NH2 group.

[0064] In this disclosure, the term "cyano" refers to a -CN group.

[0065] In the present disclosure, the term "hydrocarbyl" refers to an aliphatic hydrocarbon group. The hydrocarbyl portion can be a "saturated hydrocarbyl" group, meaning that it does not contain any alkene or alkyne moieties. The hydrocarbyl portion can also be an "unsaturated hydrocarbyl" portion, meaning that it contains at least one alkene or alkyne moiety. The "alkene" portion refers to a straight or branched hydrocarbon chain group consisting of two to eight carbon atoms and at least one carbon-carbon double bond, and connected to the rest of the molecule by a single bond, such as vinyl, prop-1-enyl, but-1-enyl, pent-1-enyl, pent-1,4-dienyl, etc., and the "alkyne" portion refers to a straight or branched hydrocarbon chain group consisting of two to eight carbon atoms and at least one carbon-carbon triple bond, and connected to the rest of the molecule by a single bond. The hydrocarbyl portion, whether saturated or unsaturated, can be branched or straight-chain.

[0066] The hydrocarbyl group can have from 1 to 8 carbon atoms (each occurrence in this disclosure of a numerical range such as "1 to 8" refers to each integer in the given range; e.g., "1 to 8" means that the hydrocarbyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, etc., up to and including 8 carbon atoms, although this definition also covers occurrences of the term "hydrocarbyl" without specifying a numerical range).

[0067] The hydrocarbyl group may be optionally substituted, i.e., substituted or unsubstituted. When substituted, the substituent groups are individually and independently selected from one or more of the following: cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, hydrocarbyloxy, aryloxy, mercapto, hydrocarbylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxyl, O-carboxyl, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, -NR'R" (R' and R" are hydrocarbyl as defined herein), or amino, including mono- and di-substituted amino groups, and protected derivatives thereof. Typical hydrocarbyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, vinyl, propenyl, butenyl, ethynyl, propynyl and butynyl. Whenever a substituent is described as being "optionally substituted," the substituent may be substituted by one of the substituents described above.

[0068] In certain embodiments, "C1-C4 hydrocarbyl" refers to a hydrocarbyl group as defined above containing one to four carbon atoms. The C1-C4 hydrocarbyl group may be optionally substituted as defined for a hydrocarbyl group.

[0069] In certain embodiments, a "C1-C4 hydrocarbyl" may be a C1-C4 alkyl group. A C1-C4 alkyl group may be optionally substituted as defined for a hydrocarbyl group.

[0070] In certain embodiments, "C1-C6 hydrocarbyl" refers to a hydrocarbyl group as defined above containing one to six carbon atoms. The C1-C6 hydrocarbyl group may be optionally substituted as defined for a hydrocarbyl group.

[0071] In certain embodiments, a "C1-C6 hydrocarbyl" may be a C1-C6 alkyl group. A C1-C6 alkyl group may be optionally substituted as defined for a hydrocarbyl group.

[0072] In certain embodiments, "C1-C 12 "Hydrocarbyl" refers to a hydrocarbon group as defined above containing from one to twelve carbon atoms. 12 The hydrocarbyl group may be optionally substituted as defined for a hydrocarbyl group.

[0073] In certain embodiments, "C1-C 12 The hydrocarbon group can be C1-C 12 Alkyl group. C1-C 12 Alkyl groups may be optionally substituted as defined for hydrocarbyl groups.

[0074] In certain embodiments, "C2-C6 hydrocarbyl" refers to a hydrocarbyl group as defined above containing two to six carbon atoms. The C2-C6 hydrocarbyl group may be optionally substituted as defined for a hydrocarbyl group.

[0075] In certain embodiments, a "C2-C6 hydrocarbyl" may be a C2-C6 alkyl group. A C2-C6 alkyl group may be optionally substituted as defined for a hydrocarbyl group.

[0076] In certain embodiments, a "C2-C6 alkyl" may be a C2-C6 alkenyl group. A C2-C6 alkenyl group may be optionally substituted as defined for an alkyl group.

[0077] In certain embodiments, a "C2-C6 alkyl" may be a C2-C6 alkynyl group. A C2-C6 alkynyl group may be optionally substituted as defined for an alkyl group.

[0078] In certain embodiments, "C3-C6 hydrocarbyl" refers to a hydrocarbyl group as defined above containing three to six carbon atoms. A C3-C6 hydrocarbyl group may be optionally substituted as defined for a hydrocarbyl group.

[0079] In certain embodiments, a "C3-C6 hydrocarbyl" may be a C3-C6 alkyl group. A C3-C6 alkyl group may be optionally substituted as defined for a hydrocarbyl group.

[0080] In certain embodiments, a "C3-C6 alkyl" may be a C3-C6 alkenyl group. A C3-C6 alkenyl group may be optionally substituted as defined for an alkyl group.

[0081] In certain embodiments, a "C3-C6 alkyl" may be a C3-C6 alkynyl group. A C3-C6 alkynyl group may be optionally substituted as defined for an alkyl group.

[0082] In certain embodiments, "C3-C 12 "Hydrocarbyl" refers to a hydrocarbon group as defined above containing three to twelve carbon atoms. 12 The hydrocarbyl group may be optionally substituted as defined for a hydrocarbyl group.

[0083] In certain embodiments, "C3-C 12 The hydrocarbon group can be C3-C 12 Alkyl group. C3-C 12 Alkyl groups may be optionally substituted as defined for hydrocarbyl groups.

[0084] In certain embodiments, "C3-C 12 The hydrocarbon group can be C3-C 12 Alkenyl group. C3-C 12 Alkenyl groups may be optionally substituted as defined for hydrocarbyl groups.

[0085] In certain embodiments, "C3-C 12 The hydrocarbon group can be C3-C 12 Alkynyl group. C3-C 12 Alkynyl groups may be optionally substituted as defined for hydrocarbyl groups.

[0086] In certain embodiments, "C6-C 12 "Hydrocarbyl" refers to a hydrocarbon group as defined above containing six to twelve carbon atoms. 12 The hydrocarbyl group may be optionally substituted as defined for a hydrocarbyl group.

[0087] In certain embodiments, "C6-C 12 The hydrocarbon group can be C6-C 12 Alkyl group. C6-C 12 Alkyl groups may be optionally substituted as defined for hydrocarbyl groups.

[0088] In certain embodiments, "C6-C12 The hydrocarbon group can be C6-C 12 Alkenyl group. C6-C 12 Alkenyl groups may be optionally substituted as defined for hydrocarbyl groups.

[0089] In certain embodiments, "C6-C 12 The hydrocarbon group can be C6-C 12 Alkynyl group. C6-C 12 Alkynyl groups may be optionally substituted as defined for hydrocarbyl groups.

[0090] In certain embodiments, "C7-C 12 "Hydrocarbyl" refers to a hydrocarbon group as defined above containing seven to twelve carbon atoms. 12 The hydrocarbyl group may be optionally substituted as defined for a hydrocarbyl group.

[0091] In certain embodiments, "C7-C 12 The hydrocarbon group can be C7-C 12 Alkyl group. C7-C 12 Alkyl groups may be optionally substituted as defined for hydrocarbyl groups.

[0092] In certain embodiments, "C7-C 12 The hydrocarbon group can be C7-C 12 Alkenyl group. C7-C 12 Alkenyl groups may be optionally substituted as defined for hydrocarbyl groups.

[0093] In certain embodiments, "C7-C 12 The hydrocarbon group can be C7-C 12 Alkynyl group. C7-C 12 Alkynyl groups may be optionally substituted as defined for hydrocarbyl groups.

[0094] As used herein, the term "alkylene" refers to a straight or branched divalent hydrocarbon chain that links the rest of the molecule to a radical, consisting solely of carbon and hydrogen, containing no unsaturated bonds, and having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. The alkylene group is attached to the rest of the molecule and to the radical group through a single bond. The points of attachment of the alkylene group to the rest of the molecule and to the radical group can be through one carbon or any two carbon atoms within the chain.

[0095] In the present disclosure, the term "alkyloxy" refers to the general formula -O-alkyl, wherein alkyl is as defined in the present disclosure. Illustrative examples of alkyloxy include, but are not limited to, methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, and tert-pentoxy.

[0096] In the present disclosure, the term "aryl" refers to a carbocyclic ring (all carbon) or two or more fused rings (rings sharing two adjacent carbon atoms) having a completely delocalized pi electron system. Aryl groups include, but are not limited to, fluorenyl, phenyl, and naphthyl. Aryl groups can, for example, have five to twelve carbon atoms. The aryl groups of the present disclosure can be substituted or unsubstituted. When substituted, the hydrogen atoms are replaced by one or more groups independently selected from the group consisting of hydrocarbyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, protected hydroxy, hydrocarbyloxy, aryloxy, mercapto, hydrocarbylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, -NR'R" (R' and R" are hydrocarbyl as defined in the present disclosure), or protected amino. Whenever a substituent is described as being "optionally substituted," the substituent may be substituted by one of the substituents described above.

[0097] In the present disclosure, the term "heteroaryl" refers to a 5- to 18-membered aromatic ring group consisting of one to seventeen carbon atoms and one to ten heteroatoms selected from nitrogen, oxygen, and sulfur. In certain embodiments, the heteroaryl group may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heteroaryl group may be optionally oxidized; the nitrogen atom may be optionally quaternized. Illustrative examples of heteroaryl groups include, but are not limited to, azaquinolyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepanyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyrone, benzofuranyl, benzofuranone, benzothiophenyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, diphenyl The heteroaryl groups of the present disclosure may be substituted or unsubstituted. When substituted, the hydrogen atoms are replaced by one or more groups independently selected from the group consisting of hydrocarbyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, protected hydroxy, hydrocarbyloxy, aryloxy, mercapto, hydrocarbylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, -NR'R" (R' and R" are hydrocarbyl as defined in the present disclosure), or protected amino. Whenever a substituent is described as being "optionally substituted," the substituent may be substituted by one of the substituents described above.

[0098] In the present disclosure, the term "cycloalkyl" refers to a stable non-aromatic monocyclic or bicyclic hydrocarbon group consisting solely of carbon and hydrogen atoms, having from three to fifteen carbon atoms, in certain embodiments from three to twelve carbon atoms, and which is saturated or unsaturated and is attached to the rest of the molecule by a single bond, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclodecyl, and the like. Unless otherwise expressly stated in the present disclosure, the term "cycloalkyl" is intended to include cycloalkyl as defined above optionally substituted with one or more substituents selected from the group consisting of cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkyloxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfinylamino, N-sulfinylamino, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, -NR'R" (R' and R" are alkyl as defined in the present disclosure), or amino including mono- and di-substituted amino groups, and protected derivatives thereof.

[0099] In certain embodiments, "C3-C6 cycloalkyl" refers to a cycloalkyl group as defined above having three to six carbon atoms. The C3-C6 cycloalkyl group may be optionally substituted as defined above for cycloalkyl.

[0100] In certain embodiments, "C3-C 10 "Cycloalkyl" refers to a cycloalkyl group as defined above having three to ten carbon atoms. 10 The cycloalkyl group may be optionally substituted as defined above for a cycloalkyl group.

[0101] In certain embodiments, "C3-C 12 "Cycloalkyl" refers to a cycloalkyl group as defined above having three to twelve carbon atoms. 12 The cycloalkyl group may be optionally substituted as defined above for a cycloalkyl group.

[0102] In the present disclosure, the term "heterocycloalkyl" refers to a stable three- to twelve-membered non-aromatic ring group consisting of carbon atoms and one to five heteroatoms selected from nitrogen, oxygen, and sulfur. Examples of such heterocyclyl groups include, but are not limited to, dioxolane, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thimorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl.

[0103] In the present disclosure, the term "compound of the present disclosure or a pharmaceutically acceptable salt thereof" refers to the compound represented by the general formula (I) of the present disclosure and a pharmaceutically acceptable salt thereof, as well as any specific compound falling within the general formula (I) and a pharmaceutically acceptable salt thereof.

[0104] In this disclosure, the term "mammal" refers to animals including, for example, dogs, cats, cows, sheep, horses, and humans, etc. In certain embodiments, the mammal includes humans.

[0105] In this disclosure, the term "patient" refers to animals (e.g., humans), companion animals (e.g., dogs, cats, or horses), and livestock (e.g., cattle, pigs, and sheep). In certain embodiments, the patient is a mammal, including males and females. In certain embodiments, the patient is a human.

[0106] In this disclosure, the term "pharmaceutically acceptable" refers to carriers, vehicles, diluents, excipients and / or salts that must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

[0107] In this disclosure, the terms “optional” or “optionally” mean that the subsequently described event or circumstance can or cannot occur, and the description includes instances where the event or circumstance occurs and instances where it does not.

[0108] In the present disclosure, the term "pharmaceutically acceptable excipients" includes but is not limited to any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the U.S. Food and Drug Administration for use in humans or animals, and various forms of carriers that have no side effects on the composition of the pharmaceutical composition.

[0109] In this disclosure, the term "carrier" is defined as a compound that facilitates the introduction of a compound into cells or tissues. For example, dimethyl sulfoxide (DMSO) is commonly used as a carrier because it facilitates the introduction of certain organic compounds into cells or tissues of an organism.

[0110] In the present disclosure, the term "pharmaceutically acceptable salt" includes "acceptable acid addition salts" and "acceptable base addition salts".

[0111] In this disclosure, the term "acceptable acid addition salts" refers to those salts which retain the biological effectiveness and properties of the free bases and which are biologically or otherwise suitable and are formed using inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzenecarboxylic acid, 4-acetamidobenzenecarboxylic acid, camphoric acid, camphor-10-sulfonic acid, decanoic acid, hexanoic acid, octanoic acid, carbonic acid, cinnamic acid, citric acid, cyclohexanesulfamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, Ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, mucic acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphate, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, etc.

[0112] In this disclosure, the term "acceptable base addition salts" refers to salts that retain the biological effectiveness and properties of the free acids, and the base addition salts are biologically or otherwise suitable. These salts are prepared by adding inorganic or organic bases to the free acids. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. In certain embodiments, the inorganic salts are ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrazine, choline, betaine, benzylamine, phenylethylenediamine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. In certain embodiments, the organic base is isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

[0113] As used herein, the term "pharmaceutical composition" refers to a formulation of a compound described herein and a medium generally accepted in the art for delivering the bioactive compound to mammals, such as humans. Such a medium includes any pharmaceutically acceptable carrier, diluent, or excipient.

[0114] In the present disclosure, the term "therapeutically effective amount" refers to an amount of a compound or combination of compounds that ameliorates, reduces, or eliminates a particular disease or condition and symptoms of a particular disease or condition, or prevents or delays the onset of a particular disease or condition or symptoms of a particular disease or condition. The amount of a compound described in the present disclosure that constitutes a "therapeutically effective amount" will vary depending on the compound, the disease state and its severity, and the age, weight, etc. of the mammal to be treated, but the amount of a compound described in the present disclosure can be routinely determined by one skilled in the art based on their own knowledge and this disclosure.

[0115] As used herein, "treating" or "treatment" encompasses treating a relevant disease or condition in a mammal, such as a human, suffering from the relevant disease or condition, and includes:

[0116] (i) preventing a disease or disease state from occurring in a mammal, particularly where the mammal is susceptible to said disease state but has not yet been diagnosed with such disease state;

[0117] (ii) inhibiting the disease or disease state, i.e., preventing its occurrence; or

[0118] (iii) ameliorating the disease or condition, even if the disease or condition regresses or does not progress.

[0119] In this disclosure, the term "prevent" or "preventing" refers to preventing the onset, recurrence, or spread of a disease or disease state, or one or more symptoms thereof.

[0120] In this disclosure, the term "prophylactically effective amount" refers to an amount of a compound or combination of compounds sufficient to prevent a disease or disease state, or to prevent its recurrence or spread. The amount of a compound described in this disclosure that constitutes a "prophylactically effective amount" will vary depending on the compound, the disease state and its severity, and the age, weight, etc. of the mammal to be treated, but the amount of a compound described in this disclosure can be routinely determined by one skilled in the art based on their own knowledge and this disclosure.

[0121] As used in this disclosure, the terms "disease" and "disease state" may be used interchangeably, or may be distinct in that a particular disease or disease state may have no known causative agent (and therefore cannot be explained etiologically) and therefore is not recognized as a disease, but rather is considered an undesirable disease state or condition in which clinicians have identified a more or less specific constellation of symptoms.

[0122] In the present disclosure, the term "tuberculosis (TB)" refers to a disease caused by infection with Mycobacterium tuberculosis (MTB). DETAILED DESCRIPTION

[0123] In one aspect, the present disclosure relates to a method for preventing or treating tuberculosis (TB), comprising administering to an individual in need thereof a preventive or therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof,

[0124] in

[0125] R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0126] R3 is selected from an optionally substituted amino group;

[0127] R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0128] R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy;

[0129] R6 is selected from a chemical bond or an optionally substituted alkylene group;

[0130] R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and

[0131] X is selected from CH or N.

[0132] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C6 alkyl, optionally substituted C3-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3 ... 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0133] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted cycloalkyl.

[0134] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, or optionally substituted C3-C6 cycloalkyl.

[0135] In certain embodiments, R1 and R2 are each independently selected from hydrogen or cyclopropyl.

[0136] In certain embodiments, R3 is selected from unsubstituted amino or optionally substituted alkyl-substituted amino.

[0137] In certain embodiments, R3 is selected from unsubstituted amino or amino substituted with an optionally substituted C1-C6 alkyl group.

[0138] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, or optionally substituted aryl-substituted alkyl-substituted amino.

[0139] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino or optionally substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0140] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0141] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0142] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, alkynyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted silyl-substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0143] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino, C2-C6 alkynyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted silyl substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0144] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, alkynyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkyl-substituted silyl-substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0145] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12Aryl substituted C1-C6 alkyl substituted amino, C2-C6 alkynyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted C1-C6 alkyl substituted silyl substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0146] In certain embodiments, R3 is selected from amino, hydroxyethylamino, iodobenzylamino, vinylbenzylamino, ethynylbenzylamino, or triethylsilylethynylbenzylamino.

[0147] In certain embodiments, R3 is selected from NH2,

[0148] In certain embodiments, R4 is selected from hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0149] In certain embodiments, R4 is selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, halogen-substituted aryl, optionally substituted alkoxy-substituted aryl, or unsubstituted heteroaryl.

[0150] In certain embodiments, R4 is selected from hydrogen, halogen, unsubstituted C1-C6 alkyl, unsubstituted C3-C 15 Cycloalkyl, halogen-substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl or unsubstituted C1-C 17 Heteroaryl.

[0151] In certain embodiments, R4 is selected from hydrogen, bromo, methyl, cyclopropyl, fluoro-substituted phenyl, methoxy-substituted phenyl, or pyridyl.

[0152] In certain embodiments, R4 is selected from H, Br, -CH3,

[0153] In certain embodiments, R5 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, or optionally substituted C1-C6 alkoxy.

[0154] In certain embodiments, R5 is selected from hydrogen or unsubstituted alkyl.

[0155] In certain embodiments, R5 is selected from hydrogen or unsubstituted C1-C6 alkyl.

[0156] In certain embodiments, R5 is selected from hydrogen or methyl.

[0157] In certain embodiments, R6 is selected from a chemical bond or an optionally substituted C1-C 12 Alkylene.

[0158] In certain embodiments, R6 is selected from a bond, an unsubstituted alkylene group, or an optionally substituted alkylene group.

[0159] In certain embodiments, R6 is selected from a chemical bond, an unsubstituted C1-C 12 Alkylene or optionally substituted C1-C6 alkyl substituted C1-C 12 Alkylene.

[0160] In certain embodiments, R6 is selected from a bond, -CH2-, -CH2CH2-, or -CH(CH3)-.

[0161] In certain embodiments, R7 is selected from optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0162] In certain embodiments, R is selected from optionally substituted aryl-substituted alkyl, alkenyl, optionally substituted aryl-substituted alkenyl, optionally substituted aryl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted aryl-substituted aryl, optionally substituted heteroaryl-substituted aryl, optionally substituted aryloxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted aryl-substituted heteroaryl.

[0163] In certain embodiments, R7 is selected from optionally substituted C5-C 12Aryl-substituted C1-C6 alkyl, C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl-substituted C2-C6 alkynyl, unsubstituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C3-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryl-substituted C5-C 12 Aryl, optionally substituted C1-C 17 Heteroaryl-substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryloxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted C5-C 12 Aryl-substituted C1-C 17 Heteroaryl.

[0164] In certain embodiments, R7 is selected from optionally substituted phenyl-substituted alkyl, alkenyl, optionally substituted phenyl-substituted alkenyl, optionally substituted phenyl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted phenyl-substituted aryl, optionally substituted pyridyl-substituted aryl, optionally substituted phenoxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted phenyl-substituted heteroaryl.

[0165] In certain embodiments, R7 is selected from the group consisting of optionally substituted phenyl-substituted C1-C6 alkyl, C2-C6 alkenyl, optionally substituted phenyl-substituted C2-C6 alkenyl, optionally substituted phenyl-substituted C2-C6 alkynyl, unsubstituted C3-C6 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted phenyl substituted C5-C 12 Aryl, optionally substituted pyridyl substituted C5-C 12 Aryl, optionally substituted phenoxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted phenyl substituted C1-C 17 Heteroaryl.

[0166] In certain embodiments, R7 is selected from optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkynyl, optionally substituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryl-substituted C5-C 12 Aryl, optionally substituted C1-C 17 Heteroaryl-substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryloxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted C5-C 12 Aryl-substituted C1-C 17 Heteroaryl.

[0167] In certain embodiments, R is selected from methyl substituted by fluorophenyl, vinyl, vinyl substituted by methoxycarbonyl, propenyl substituted by methoxycarbonyl, propenyl substituted by phenyl, propynyl substituted by phenyl, cyclopentyl, fluoro substituted phenyl, chloro substituted phenyl, bromo substituted phenyl, nitro substituted phenyl, ethyl substituted phenyl, isopropyl substituted phenyl, vinyl substituted phenyl, ethynyl substituted phenyl, cyclopropylethynyl substituted phenyl, triethylsilylethynyl substituted phenyl, phenylethynyl substituted phenyl, propynyl substituted phenyl, aminopropynyl substituted phenyl, dimethylaminopropynyl substituted phenyl , phenyl substituted by methylbutynyl, phenyl substituted by tert-butoxycarbonylaminopropynyl, phenyl substituted by methoxy, phenyl dimethoxy, phenyl trimethoxy, phenyl substituted by phenoxy, phenyl substituted by boronate, biphenyl, pyridyl substituted by phenyl, naphthyl, bromo-substituted naphthyl, methyl-substituted naphthyl, isoquinolyl, thienyl substituted by cyano, fluoro-substituted pyridyl, isopropyl-substituted pyridyl, trifluoromethyl-substituted pyridyl, methoxy-substituted pyridyl, cyano-substituted pyridyl, phenyl substituted by pyridyl, trifluoromethyl-substituted thiazolyl or benzo[d][1,3]dioxolyl.

[0168] In certain embodiments, R7 is selected from vinyl,

[0169] In certain embodiments, X is selected from CH.

[0170] In certain embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from:

[0171] 7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0172] 2-((7-([1,1'-biphenyl]-4-ylmethyl)-3-amino-7H-pyrrolo[3,2-f]quinazolin-1-yl)amino)ethan-1-ol;

[0173] 7-(3-phenylpropyl-2-yn-1-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0174] 7-cinnamyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0175] 7-(3-phenoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0176] 7-(4-ethynylbenzyl)-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0177] (Z)-2-cyano-1-(1-(4-ethynylbenzyl)-2-methyl-1H-benzimidazol-5-yl)guanidine;

[0178] 7-(4-isopropylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0179] N 3 -cyclopropyl-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0180] 7-(4-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0181] 7-(Cyclopentylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0182] 7-(3-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0183] 7-(3,4-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0184] 7-(3,5-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0185] 7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0186] tert-Butyl (3-(4-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)prop-2-yn-1-yl)carbamate;

[0187] N 3 -cyclopropyl-7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0188] N 3 -cyclopropyl-7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0189] N 3 -cyclopropyl-7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0190] N 3 -cyclopropyl-7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0191] 7-(4-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0192] 7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0193] 7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0194] 7-(4-(3-aminopropyl-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0195] 7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0196] 7-(Naphth-2-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0197] N 1,7 -bis(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0198] N 1,7 -bis(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0199] N 1 -(4-iodobenzyl)-7-(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0200] 7-(4-ethynylbenzyl)-N 1 -(4-iodobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0201] 7-(4-Ethylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0202] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile;

[0203] 7-(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0204] N 1,7 -bis(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0205] 7-(4-nitrobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0206] 7-allyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0207] 7-(1-(4-fluorophenyl)ethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0208] 7-(Naphthalen-1-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0209] 7-(Quinolin-8-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0210] 7-(4-Fluorophenylethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0211] 7-(4-Fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0212] 7-(4-Fluorobenzyl)-5-(4-methoxyphenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0213] 7-(4-methylnaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0214] 7-(4-Fluorobenzyl)-5-(pyridin-3-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0215] 7-(4-bromonaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0216] 7-((6-fluoropyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0217] 5-Bromo-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0218] 5-Bromo-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0219] 7-((6-fluoropyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0220] 5-cyclopropyl-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0221] 7-((6-(trifluoromethyl)pyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0222] (4-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)boronic acid;

[0223] 7-(4-Fluorobenzyl)-5-(4-fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0224] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)nicotinonitrile;

[0225] Methyl 2-((1,3-diamino-5-bromo-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate;

[0226] 7-(4-Fluorobenzyl)-5-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0227] 7-((2-fluoropyridin-4-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0228] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile;

[0229] 7-((5-phenylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0230] 7-((5-isopropylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0231] 7-(2-(trifluoromethyl)thiazol-5-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0232] 7-(4-(pyridin-2-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0233] Methyl 2-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate;

[0234] 7-(4-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0235] N 7 -(4-fluorobenzyl)quinazoline-2,4,7-triamine;

[0236] 7-(2-chloro-4-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0237] 7-(3,5-dimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0238] 7-(6-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0239] 7-(2,3-Dichlorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0240] 7-(Benzo[d][1,3]dioxol-5-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0241] 7-(5-bromo-2-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; and

[0242] 7-(3,4,5-Trimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

[0243] In certain embodiments, the methods of the present disclosure further comprise administering to the individual other drugs for preventing or treating tuberculosis.

[0244] In certain embodiments, illustrative examples of other drugs for preventing or treating tuberculosis that can be used in the present disclosure include, but are not limited to, isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, pyrazinamide, sodium para-aminosalicylate, rifapentine, and prothionamide.

[0245] In another aspect, the present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for preventing or treating tuberculosis (TB).

[0246] in

[0247] R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0248] R3 is selected from an optionally substituted amino group;

[0249] R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0250] R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy;

[0251] R6 is selected from a chemical bond or an optionally substituted alkylene group;

[0252] R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and

[0253] X is selected from CH or N.

[0254] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C6 alkyl, optionally substituted C3-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3 ... 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0255] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted cycloalkyl.

[0256] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, or optionally substituted C3-C6 cycloalkyl.

[0257] In certain embodiments, R1 and R2 are each independently selected from hydrogen or cyclopropyl.

[0258] In certain embodiments, R3 is selected from unsubstituted amino or optionally substituted alkyl-substituted amino.

[0259] In certain embodiments, R3 is selected from unsubstituted amino or amino substituted with an optionally substituted C1-C6 alkyl group.

[0260] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, or optionally substituted aryl-substituted alkyl-substituted amino.

[0261] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino or optionally substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0262] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0263] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted C2-C6 alkynyl substituted C5-C12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0264] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, alkynyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted silyl-substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0265] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino, C2-C6 alkynyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted silyl substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0266] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, alkynyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkyl-substituted silyl-substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0267] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino, C2-C6 alkynyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted C1-C6 alkyl substituted silyl substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0268] In certain embodiments, R3 is selected from amino, hydroxyethylamino, iodobenzylamino, vinylbenzylamino, ethynylbenzylamino, or triethylsilylethynylbenzylamino.

[0269] In certain embodiments, R3 is selected from NH2,

[0270] In certain embodiments, R4 is selected from hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0271] In certain embodiments, R4 is selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, halogen-substituted aryl, optionally substituted alkoxy-substituted aryl, or unsubstituted heteroaryl.

[0272] In certain embodiments, R4 is selected from hydrogen, halogen, unsubstituted C1-C6 alkyl, unsubstituted C3-C 15 Cycloalkyl, halogen-substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl or unsubstituted C1-C 17 Heteroaryl.

[0273] In certain embodiments, R4 is selected from hydrogen, bromo, methyl, cyclopropyl, fluoro-substituted phenyl, methoxy-substituted phenyl, or pyridyl.

[0274] In certain embodiments, R4 is selected from H, Br, -CH3,

[0275] In certain embodiments, R5 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, or optionally substituted C1-C6 alkoxy.

[0276] In certain embodiments, R5 is selected from hydrogen or unsubstituted alkyl.

[0277] In certain embodiments, R5 is selected from hydrogen or unsubstituted C1-C6 alkyl.

[0278] In certain embodiments, R5 is selected from hydrogen or methyl.

[0279] In certain embodiments, R6 is selected from a chemical bond or an optionally substituted C1-C 12 Alkylene.

[0280] In certain embodiments, R6 is selected from a bond, an unsubstituted alkylene group, or an optionally substituted alkylene group.

[0281] In certain embodiments, R6 is selected from a chemical bond, an unsubstituted C1-C 12 Alkylene or optionally substituted C1-C6 alkyl substituted C1-C 12 Alkylene.

[0282] In certain embodiments, R6 is selected from a bond, -CH2-, -CH2CH2-, or -CH(CH3)-.

[0283] In certain embodiments, R7 is selected from optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0284] In certain embodiments, R7 is selected from optionally substituted aryl-substituted alkyl, alkenyl, optionally substituted aryl-substituted alkenyl, optionally substituted aryl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted aryl-substituted aryl, optionally substituted heteroaryl-substituted aryl, optionally substituted aryloxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted aryl-substituted heteroaryl.

[0285] In certain embodiments, R7 is selected from optionally substituted C5-C 12 Aryl-substituted C1-C6 alkyl, C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl-substituted C2-C6 alkynyl, unsubstituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C3-C6 alkenyl substituted C5-C 12Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryl-substituted C5-C 12 Aryl, optionally substituted C1-C 17 Heteroaryl-substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryloxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted C5-C 12 Aryl-substituted C1-C 17 Heteroaryl.

[0286] In certain embodiments, R7 is selected from optionally substituted phenyl-substituted alkyl, alkenyl, optionally substituted phenyl-substituted alkenyl, optionally substituted phenyl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted phenyl-substituted aryl, optionally substituted pyridyl-substituted aryl, optionally substituted phenoxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted phenyl-substituted heteroaryl.

[0287] In certain embodiments, R7 is selected from the group consisting of optionally substituted phenyl-substituted C1-C6 alkyl, C2-C6 alkenyl, optionally substituted phenyl-substituted C2-C6 alkenyl, optionally substituted phenyl-substituted C2-C6 alkynyl, unsubstituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkenyl substituted C5-C 12Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted phenyl substituted C5-C 12 Aryl, optionally substituted pyridyl substituted C5-C 12 Aryl, optionally substituted phenoxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted phenyl substituted C1-C 17 Heteroaryl.

[0288] In certain embodiments, R7 is selected from optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkynyl, optionally substituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryl-substituted C5-C 12 Aryl, optionally substituted C1-C 17 Heteroaryl-substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryloxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted C5-C 12 Aryl-substituted C1-C 17 Heteroaryl.

[0289] In certain embodiments, R is selected from methyl substituted by fluorophenyl, vinyl, vinyl substituted by methoxycarbonyl, propenyl substituted by methoxycarbonyl, propenyl substituted by phenyl, propynyl substituted by phenyl, cyclopentyl, fluoro substituted phenyl, chloro substituted phenyl, bromo substituted phenyl, nitro substituted phenyl, ethyl substituted phenyl, isopropyl substituted phenyl, vinyl substituted phenyl, ethynyl substituted phenyl, cyclopropylethynyl substituted phenyl, triethylsilylethynyl substituted phenyl, phenylethynyl substituted phenyl, propynyl substituted phenyl, aminopropynyl substituted phenyl, dimethylaminopropynyl substituted phenyl , phenyl substituted by methylbutynyl, phenyl substituted by tert-butoxycarbonylaminopropynyl, phenyl substituted by methoxy, phenyl dimethoxy, phenyl trimethoxy, phenyl substituted by phenoxy, phenyl substituted by boronate, biphenyl, pyridyl substituted by phenyl, naphthyl, bromo-substituted naphthyl, methyl-substituted naphthyl, isoquinolyl, thienyl substituted by cyano, fluoro-substituted pyridyl, isopropyl-substituted pyridyl, trifluoromethyl-substituted pyridyl, methoxy-substituted pyridyl, cyano-substituted pyridyl, phenyl substituted by pyridyl, trifluoromethyl-substituted thiazolyl or benzo[d][1,3]dioxolyl.

[0290] In certain embodiments, R7 is selected from vinyl,

[0291] In certain embodiments, X is selected from CH.

[0292] In certain embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from:

[0293] 7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0294] 2-((7-([1,1'-biphenyl]-4-ylmethyl)-3-amino-7H-pyrrolo[3,2-f]quinazolin-1-yl)amino)ethan-1-ol;

[0295] 7-(3-phenylpropyl-2-yn-1-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0296] 7-cinnamyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0297] 7-(3-phenoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0298] 7-(4-ethynylbenzyl)-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0299] (Z)-2-cyano-1-(1-(4-ethynylbenzyl)-2-methyl-1H-benzimidazol-5-yl)guanidine;

[0300] 7-(4-isopropylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0301] N 3 -cyclopropyl-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0302] 7-(4-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0303] 7-(Cyclopentylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0304] 7-(3-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0305] 7-(3,4-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0306] 7-(3,5-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0307] 7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0308] tert-Butyl (3-(4-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)prop-2-yn-1-yl)carbamate;

[0309] N 3 -cyclopropyl-7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0310] N 3 -cyclopropyl-7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0311] N 3 -cyclopropyl-7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0312] N 3 -cyclopropyl-7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0313] 7-(4-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0314] 7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0315] 7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0316] 7-(4-(3-aminopropyl-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0317] 7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0318] 7-(Naphth-2-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0319] N 1,7 -bis(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0320] N 1,7 -bis(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0321] N 1 -(4-iodobenzyl)-7-(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0322] 7-(4-ethynylbenzyl)-N 1 -(4-iodobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0323] 7-(4-Ethylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0324] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile;

[0325] 7-(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0326] N 1,7 -bis(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0327] 7-(4-nitrobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0328] 7-allyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0329] 7-(1-(4-fluorophenyl)ethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0330] 7-(Naphthalen-1-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0331] 7-(Quinolin-8-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0332] 7-(4-Fluorophenylethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0333] 7-(4-Fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0334] 7-(4-Fluorobenzyl)-5-(4-methoxyphenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0335] 7-(4-methylnaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0336] 7-(4-Fluorobenzyl)-5-(pyridin-3-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0337] 7-(4-bromonaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0338] 7-((6-fluoropyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0339] 5-Bromo-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0340] 5-Bromo-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0341] 7-((6-fluoropyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0342] 5-cyclopropyl-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0343] 7-((6-(trifluoromethyl)pyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0344] (4-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)boronic acid;

[0345] 7-(4-Fluorobenzyl)-5-(4-fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0346] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)nicotinonitrile;

[0347] Methyl 2-((1,3-diamino-5-bromo-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate;

[0348] 7-(4-Fluorobenzyl)-5-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0349] 7-((2-fluoropyridin-4-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0350] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile;

[0351] 7-((5-phenylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0352] 7-((5-isopropylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0353] 7-(2-(trifluoromethyl)thiazol-5-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0354] 7-(4-(pyridin-2-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0355] Methyl 2-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate;

[0356] 7-(4-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0357] N 7 -(4-fluorobenzyl)quinazoline-2,4,7-triamine;

[0358] 7-(2-chloro-4-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0359] 7-(3,5-dimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0360] 7-(6-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0361] 7-(2,3-Dichlorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0362] 7-(Benzo[d][1,3]dioxol-5-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0363] 7-(5-bromo-2-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; and

[0364] 7-(3,4,5-Trimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

[0365] In another aspect, the present disclosure relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing or treating tuberculosis (TB).

[0366] in

[0367] R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0368] R3 is selected from an optionally substituted amino group;

[0369] R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0370] R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy;

[0371] R6 is selected from a chemical bond or an optionally substituted alkylene group;

[0372] R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and

[0373] X is selected from CH or N.

[0374] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C6 alkyl, optionally substituted C3-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3 ... 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0375] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted cycloalkyl.

[0376] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, or optionally substituted C3-C6 cycloalkyl.

[0377] In certain embodiments, R1 and R2 are each independently selected from hydrogen or cyclopropyl.

[0378] In certain embodiments, R3 is selected from unsubstituted amino or optionally substituted alkyl-substituted amino.

[0379] In certain embodiments, R3 is selected from unsubstituted amino or amino substituted with an optionally substituted C1-C6 alkyl group.

[0380] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, or optionally substituted aryl-substituted alkyl-substituted amino.

[0381] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino or optionally substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0382] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0383] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0384] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, alkynyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted silyl-substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0385] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino, C2-C6 alkynyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted silyl substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0386] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, alkynyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkyl-substituted silyl-substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0387] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino, C2-C6 alkynyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted C1-C6 alkyl substituted silyl substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0388] In certain embodiments, R3 is selected from amino, hydroxyethylamino, iodobenzylamino, vinylbenzylamino, ethynylbenzylamino, or triethylsilylethynylbenzylamino.

[0389] In certain embodiments, R3 is selected from NH2,

[0390] In certain embodiments, R4 is selected from hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C6 alkyl, optionally substituted C3-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3 ... 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0391] In certain embodiments, R4 is selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, halogen-substituted aryl, optionally substituted alkoxy-substituted aryl, or unsubstituted heteroaryl.

[0392] In certain embodiments, R4 is selected from hydrogen, halogen, unsubstituted C1-C6 alkyl, unsubstituted C3-C 15 Cycloalkyl, halogen-substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl or unsubstituted C1-C 17 Heteroaryl.

[0393] In certain embodiments, R4 is selected from hydrogen, bromo, methyl, cyclopropyl, fluoro-substituted phenyl, methoxy-substituted phenyl, or pyridyl.

[0394] In certain embodiments, R4 is selected from H, Br, -CH3,

[0395] In certain embodiments, R5 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, or optionally substituted C1-C6 alkoxy.

[0396] In certain embodiments, R5 is selected from hydrogen or unsubstituted alkyl.

[0397] In certain embodiments, R5 is selected from hydrogen or unsubstituted C1-C6 alkyl.

[0398] In certain embodiments, R5 is selected from hydrogen or methyl.

[0399] In certain embodiments, R6 is selected from a chemical bond or an optionally substituted C1-C 12 Alkylene.

[0400] In certain embodiments, R6 is selected from a bond, an unsubstituted alkylene group, or an optionally substituted alkylene group.

[0401] In certain embodiments, R6 is selected from a chemical bond, an unsubstituted C1-C 12 Alkylene or optionally substituted C1-C6 alkyl substituted C1-C 12 Alkylene.

[0402] In certain embodiments, R6 is selected from a bond, -CH2-, -CH2CH2-, or -CH(CH3)-.

[0403] In certain embodiments, R7 is selected from optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0404] In certain embodiments, R7 is selected from optionally substituted aryl-substituted alkyl, alkenyl, optionally substituted aryl-substituted alkenyl, optionally substituted aryl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted aryl-substituted aryl, optionally substituted heteroaryl-substituted aryl, optionally substituted aryloxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted aryl-substituted heteroaryl.

[0405] In certain embodiments, R7 is selected from optionally substituted C5-C 12 Aryl-substituted C1-C6 alkyl, C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl-substituted C2-C6 alkynyl, unsubstituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C3-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryl-substituted C5-C 12 Aryl, optionally substituted C1-C 17 Heteroaryl-substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryloxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted C5-C 12 Aryl-substituted C1-C17 Heteroaryl.

[0406] In certain embodiments, R7 is selected from optionally substituted phenyl-substituted alkyl, alkenyl, optionally substituted phenyl-substituted alkenyl, optionally substituted phenyl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted phenyl-substituted aryl, optionally substituted pyridyl-substituted aryl, optionally substituted phenoxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted phenyl-substituted heteroaryl.

[0407] In certain embodiments, R7 is selected from the group consisting of optionally substituted phenyl-substituted C1-C6 alkyl, C2-C6 alkenyl, optionally substituted phenyl-substituted C2-C6 alkenyl, optionally substituted phenyl-substituted C2-C6 alkynyl, unsubstituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted phenyl substituted C5-C 12 Aryl, optionally substituted pyridyl substituted C5-C 12 Aryl, optionally substituted phenoxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted phenyl substituted C1-C 17 Heteroaryl.

[0408] In certain embodiments, R7 is selected from optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkynyl, optionally substituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryl-substituted C5-C 12 Aryl, optionally substituted C1-C 17 Heteroaryl-substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryloxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted C5-C 12 Aryl-substituted C1-C 17 Heteroaryl.

[0409] In certain embodiments, R is selected from methyl substituted by fluorophenyl, vinyl, vinyl substituted by methoxycarbonyl, propenyl substituted by methoxycarbonyl, propenyl substituted by phenyl, propynyl substituted by phenyl, cyclopentyl, fluoro substituted phenyl, chloro substituted phenyl, bromo substituted phenyl, nitro substituted phenyl, ethyl substituted phenyl, isopropyl substituted phenyl, vinyl substituted phenyl, ethynyl substituted phenyl, cyclopropylethynyl substituted phenyl, triethylsilylethynyl substituted phenyl, phenylethynyl substituted phenyl, propynyl substituted phenyl, aminopropynyl substituted phenyl, dimethylaminopropynyl substituted phenyl , phenyl substituted by methylbutynyl, phenyl substituted by tert-butoxycarbonylaminopropynyl, phenyl substituted by methoxy, phenyl dimethoxy, phenyl trimethoxy, phenyl substituted by phenoxy, phenyl substituted by boronate, biphenyl, pyridyl substituted by phenyl, naphthyl, bromo-substituted naphthyl, methyl-substituted naphthyl, isoquinolyl, thienyl substituted by cyano, fluoro-substituted pyridyl, isopropyl-substituted pyridyl, trifluoromethyl-substituted pyridyl, methoxy-substituted pyridyl, cyano-substituted pyridyl, phenyl substituted by pyridyl, trifluoromethyl-substituted thiazolyl or benzo[d][1,3]dioxolyl.

[0410] In certain embodiments, R7 is selected from vinyl,

[0411] In certain embodiments, X is selected from CH.

[0412] In certain embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from:

[0413] 7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0414] 2-((7-([1,1'-biphenyl]-4-ylmethyl)-3-amino-7H-pyrrolo[3,2-f]quinazolin-1-yl)amino)ethan-1-ol;

[0415] 7-(3-phenylpropyl-2-yn-1-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0416] 7-cinnamyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0417] 7-(3-phenoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0418] 7-(4-ethynylbenzyl)-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0419] (Z)-2-cyano-1-(1-(4-ethynylbenzyl)-2-methyl-1H-benzimidazol-5-yl)guanidine;

[0420] 7-(4-isopropylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0421] N 3 -cyclopropyl-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0422] 7-(4-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0423] 7-(Cyclopentylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0424] 7-(3-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0425] 7-(3,4-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0426] 7-(3,5-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0427] 7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0428] tert-Butyl (3-(4-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)prop-2-yn-1-yl)carbamate;

[0429] N 3 -cyclopropyl-7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0430] N 3 -cyclopropyl-7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0431] N 3 -cyclopropyl-7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0432] N 3-cyclopropyl-7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0433] 7-(4-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0434] 7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0435] 7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0436] 7-(4-(3-aminopropyl-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0437] 7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0438] 7-(Naphth-2-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0439] N 1,7 -bis(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0440] N 1,7 -bis(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0441] N 1 -(4-iodobenzyl)-7-(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0442] 7-(4-ethynylbenzyl)-N 1 -(4-iodobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0443] 7-(4-Ethylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0444] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile;

[0445] 7-(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0446] N 1,7 -bis(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0447] 7-(4-nitrobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0448] 7-allyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0449] 7-(1-(4-fluorophenyl)ethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0450] 7-(Naphthalen-1-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0451] 7-(Quinolin-8-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0452] 7-(4-Fluorophenylethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0453] 7-(4-Fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0454] 7-(4-Fluorobenzyl)-5-(4-methoxyphenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0455] 7-(4-methylnaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0456] 7-(4-Fluorobenzyl)-5-(pyridin-3-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0457] 7-(4-bromonaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0458] 7-((6-fluoropyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0459] 5-Bromo-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0460] 5-Bromo-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0461] 7-((6-fluoropyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0462] 5-cyclopropyl-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0463] 7-((6-(trifluoromethyl)pyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0464] (4-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)boronic acid;

[0465] 7-(4-Fluorobenzyl)-5-(4-fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0466] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)nicotinonitrile;

[0467] Methyl 2-((1,3-diamino-5-bromo-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate;

[0468] 7-(4-Fluorobenzyl)-5-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0469] 7-((2-fluoropyridin-4-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0470] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile;

[0471] 7-((5-phenylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0472] 7-((5-isopropylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0473] 7-(2-(trifluoromethyl)thiazol-5-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0474] 7-(4-(pyridin-2-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0475] Methyl 2-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate;

[0476] 7-(4-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0477] N 7 -(4-fluorobenzyl)quinazoline-2,4,7-triamine;

[0478] 7-(2-chloro-4-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0479] 7-(3,5-dimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0480] 7-(6-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0481] 7-(2,3-Dichlorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0482] 7-(Benzo[d][1,3]dioxol-5-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0483] 7-(5-bromo-2-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; and

[0484] 7-(3,4,5-Trimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

[0485] In another aspect, the present disclosure relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in preventing or treating tuberculosis (TB).

[0486] in

[0487] R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0488] R3 is selected from an optionally substituted amino group;

[0489] R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0490] R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy;

[0491] R6 is selected from a chemical bond or an optionally substituted alkylene group;

[0492] R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and

[0493] X is selected from CH or N.

[0494] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C6 alkyl, optionally substituted C3-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3 ... 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0495] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted cycloalkyl.

[0496] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, or optionally substituted C3-C6 cycloalkyl.

[0497] In certain embodiments, R1 and R2 are each independently selected from hydrogen or cyclopropyl.

[0498] In certain embodiments, R3 is selected from unsubstituted amino or optionally substituted alkyl-substituted amino.

[0499] In certain embodiments, R3 is selected from unsubstituted amino or amino substituted with an optionally substituted C1-C6 alkyl group.

[0500] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, or optionally substituted aryl-substituted alkyl-substituted amino.

[0501] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino or optionally substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0502] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0503] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0504] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, alkynyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted silyl-substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0505] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino, C2-C6 alkynyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted silyl substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0506] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, alkynyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkyl-substituted silyl-substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0507] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino, C2-C6 alkynyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted C1-C6 alkyl substituted silyl substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0508] In certain embodiments, R3 is selected from amino, hydroxyethylamino, iodobenzylamino, vinylbenzylamino, ethynylbenzylamino, or triethylsilylethynylbenzylamino.

[0509] In certain embodiments, R3 is selected from NH2,

[0510] In certain embodiments, R4 is selected from hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0511] In certain embodiments, R4 is selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, halogen-substituted aryl, optionally substituted alkoxy-substituted aryl, or unsubstituted heteroaryl.

[0512] In certain embodiments, R4 is selected from hydrogen, halogen, unsubstituted C1-C6 alkyl, unsubstituted C3-C 15 Cycloalkyl, halogen-substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl or unsubstituted C1-C 17 Heteroaryl.

[0513] In certain embodiments, R4 is selected from hydrogen, bromo, methyl, cyclopropyl, fluoro-substituted phenyl, methoxy-substituted phenyl, or pyridyl.

[0514] In certain embodiments, R4 is selected from H, Br, -CH3,

[0515] In certain embodiments, R5 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, or optionally substituted C1-C6 alkoxy.

[0516] In certain embodiments, R5 is selected from hydrogen or unsubstituted alkyl.

[0517] In certain embodiments, R5 is selected from hydrogen or unsubstituted C1-C6 alkyl.

[0518] In certain embodiments, R5 is selected from hydrogen or methyl.

[0519] In certain embodiments, R6 is selected from a chemical bond or an optionally substituted C1-C 12 Alkylene.

[0520] In certain embodiments, R6 is selected from a bond, an unsubstituted alkylene group, or an optionally substituted alkylene group.

[0521] In certain embodiments, R6 is selected from a chemical bond, an unsubstituted C1-C 12 Alkylene or optionally substituted C1-C6 alkyl substituted C1-C 12 Alkylene.

[0522] In certain embodiments, R6 is selected from a bond, -CH2-, -CH2CH2-, or -CH(CH3)-.

[0523] In certain embodiments, R7 is selected from optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0524] In certain embodiments, R7 is selected from optionally substituted aryl-substituted alkyl, alkenyl, optionally substituted aryl-substituted alkenyl, optionally substituted aryl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted aryl-substituted aryl, optionally substituted heteroaryl-substituted aryl, optionally substituted aryloxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted aryl-substituted heteroaryl.

[0525] In certain embodiments, R7 is selected from optionally substituted C5-C 12 Aryl-substituted C1-C6 alkyl, C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl-substituted C2-C6 alkynyl, unsubstituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C3-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryl-substituted C5-C 12 Aryl, optionally substituted C1-C 17 Heteroaryl-substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryloxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted C5-C 12 Aryl-substituted C1-C17 Heteroaryl.

[0526] In certain embodiments, R7 is selected from optionally substituted phenyl-substituted alkyl, alkenyl, optionally substituted phenyl-substituted alkenyl, optionally substituted phenyl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted phenyl-substituted aryl, optionally substituted pyridyl-substituted aryl, optionally substituted phenoxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted phenyl-substituted heteroaryl.

[0527] In certain embodiments, R7 is selected from the group consisting of optionally substituted phenyl-substituted C1-C6 alkyl, C2-C6 alkenyl, optionally substituted phenyl-substituted C2-C6 alkenyl, optionally substituted phenyl-substituted C2-C6 alkynyl, unsubstituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted phenyl substituted C5-C 12 Aryl, optionally substituted pyridyl substituted C5-C 12 Aryl, optionally substituted phenoxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted phenyl substituted C1-C 17 Heteroaryl.

[0528] In certain embodiments, R7 is selected from optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkynyl, optionally substituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryl-substituted C5-C 12 Aryl, optionally substituted C1-C 17 Heteroaryl-substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryloxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted C5-C 12 Aryl-substituted C1-C 17 Heteroaryl.

[0529] In certain embodiments, R is selected from methyl substituted by fluorophenyl, vinyl, vinyl substituted by methoxycarbonyl, propenyl substituted by methoxycarbonyl, propenyl substituted by phenyl, propynyl substituted by phenyl, cyclopentyl, fluoro substituted phenyl, chloro substituted phenyl, bromo substituted phenyl, nitro substituted phenyl, ethyl substituted phenyl, isopropyl substituted phenyl, vinyl substituted phenyl, ethynyl substituted phenyl, cyclopropylethynyl substituted phenyl, triethylsilylethynyl substituted phenyl, phenylethynyl substituted phenyl, propynyl substituted phenyl, aminopropynyl substituted phenyl, dimethylaminopropynyl substituted phenyl , phenyl substituted by methylbutynyl, phenyl substituted by tert-butoxycarbonylaminopropynyl, phenyl substituted by methoxy, phenyl dimethoxy, phenyl trimethoxy, phenyl substituted by phenoxy, phenyl substituted by boronate, biphenyl, pyridyl substituted by phenyl, naphthyl, bromo-substituted naphthyl, methyl-substituted naphthyl, isoquinolyl, thienyl substituted by cyano, fluoro-substituted pyridyl, isopropyl-substituted pyridyl, trifluoromethyl-substituted pyridyl, methoxy-substituted pyridyl, cyano-substituted pyridyl, phenyl substituted by pyridyl, trifluoromethyl-substituted thiazolyl or benzo[d][1,3]dioxolyl.

[0530] In certain embodiments, R7 is selected from vinyl,

[0531] In certain embodiments, X is selected from CH.

[0532] In certain embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from:

[0533] 7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0534] 2-((7-([1,1'-biphenyl]-4-ylmethyl)-3-amino-7H-pyrrolo[3,2-f]quinazolin-1-yl)amino)ethan-1-ol;

[0535] 7-(3-phenylpropyl-2-yn-1-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0536] 7-cinnamyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0537] 7-(3-phenoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0538] 7-(4-ethynylbenzyl)-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0539] (Z)-2-cyano-1-(1-(4-ethynylbenzyl)-2-methyl-1H-benzimidazol-5-yl)guanidine;

[0540] 7-(4-isopropylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0541] N 3 -cyclopropyl-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0542] 7-(4-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0543] 7-(Cyclopentylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0544] 7-(3-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0545] 7-(3,4-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0546] 7-(3,5-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0547] 7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0548] tert-Butyl (3-(4-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)prop-2-yn-1-yl)carbamate;

[0549] N 3 -cyclopropyl-7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0550] N 3 -cyclopropyl-7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0551] N 3 -cyclopropyl-7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0552] N 3-cyclopropyl-7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0553] 7-(4-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0554] 7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0555] 7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0556] 7-(4-(3-aminopropyl-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0557] 7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0558] 7-(Naphth-2-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0559] N 1,7 -bis(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0560] N 1,7 -bis(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0561] N 1 -(4-iodobenzyl)-7-(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0562] 7-(4-ethynylbenzyl)-N 1 -(4-iodobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0563] 7-(4-Ethylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0564] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile;

[0565] 7-(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0566] N 1,7 -bis(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0567] 7-(4-nitrobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0568] 7-allyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0569] 7-(1-(4-fluorophenyl)ethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0570] 7-(Naphthalen-1-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0571] 7-(Quinolin-8-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0572] 7-(4-Fluorophenylethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0573] 7-(4-Fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0574] 7-(4-Fluorobenzyl)-5-(4-methoxyphenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0575] 7-(4-methylnaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0576] 7-(4-Fluorobenzyl)-5-(pyridin-3-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0577] 7-(4-bromonaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0578] 7-((6-fluoropyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0579] 5-Bromo-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0580] 5-Bromo-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0581] 7-((6-fluoropyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0582] 5-cyclopropyl-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0583] 7-((6-(trifluoromethyl)pyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0584] (4-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)boronic acid;

[0585] 7-(4-Fluorobenzyl)-5-(4-fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0586] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)nicotinonitrile;

[0587] Methyl 2-((1,3-diamino-5-bromo-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate;

[0588] 7-(4-Fluorobenzyl)-5-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0589] 7-((2-fluoropyridin-4-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0590] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile;

[0591] 7-((5-phenylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0592] 7-((5-isopropylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0593] 7-(2-(trifluoromethyl)thiazol-5-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0594] 7-(4-(pyridin-2-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0595] Methyl 2-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate;

[0596] 7-(4-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0597] N 7 -(4-fluorobenzyl)quinazoline-2,4,7-triamine;

[0598] 7-(2-chloro-4-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0599] 7-(3,5-dimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0600] 7-(6-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0601] 7-(2,3-Dichlorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0602] 7-(Benzo[d][1,3]dioxol-5-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0603] 7-(5-bromo-2-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; and

[0604] 7-(3,4,5-Trimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

[0605] On the other hand, the present disclosure relates to a pharmaceutical composition for preventing or treating tuberculosis (TB), comprising a preventive or therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0606] in

[0607] R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0608] R3 is selected from an optionally substituted amino group;

[0609] R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl;

[0610] R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy;

[0611] R6 is selected from a chemical bond or an optionally substituted alkylene group;

[0612] R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and

[0613] X is selected from CH or N.

[0614] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C6 alkyl, optionally substituted C3-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3 ... 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0615] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted cycloalkyl.

[0616] In certain embodiments, R1 and R2 are each independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, or optionally substituted C3-C6 cycloalkyl.

[0617] In certain embodiments, R1 and R2 are each independently selected from hydrogen or cyclopropyl.

[0618] In certain embodiments, R3 is selected from unsubstituted amino or optionally substituted alkyl-substituted amino.

[0619] In certain embodiments, R3 is selected from unsubstituted amino or amino substituted with an optionally substituted C1-C6 alkyl group.

[0620] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, or optionally substituted aryl-substituted alkyl-substituted amino.

[0621] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino or optionally substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0622] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0623] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0624] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, alkynyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted silyl-substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0625] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino, C2-C6 alkynyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted silyl substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0626] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, alkynyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkyl-substituted silyl-substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

[0627] In certain embodiments, R3 is selected from unsubstituted amino, hydroxy substituted C1-C6 alkyl substituted amino, halogen substituted C5-C6 12 Aryl substituted C1-C6 alkyl substituted amino, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino, C2-C6 alkynyl substituted C5-C 12 Aryl substituted C1-C6 alkyl substituted amino or optionally substituted C1-C6 alkyl substituted silyl substituted C2-C6 alkynyl substituted C5-C 12 Aryl-substituted C1-C6 alkyl-substituted amino.

[0628] In certain embodiments, R3 is selected from amino, hydroxyethylamino, iodobenzylamino, vinylbenzylamino, ethynylbenzylamino, or triethylsilylethynylbenzylamino.

[0629] In certain embodiments, R3 is selected from NH2,

[0630] In certain embodiments, R4 is selected from hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0631] In certain embodiments, R4 is selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, halogen-substituted aryl, optionally substituted alkoxy-substituted aryl, or unsubstituted heteroaryl.

[0632] In certain embodiments, R4 is selected from hydrogen, halogen, unsubstituted C1-C6 alkyl, unsubstituted C3-C 15 Cycloalkyl, halogen-substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl or unsubstituted C1-C 17 Heteroaryl.

[0633] In certain embodiments, R4 is selected from hydrogen, bromo, methyl, cyclopropyl, fluoro-substituted phenyl, methoxy-substituted phenyl, or pyridyl.

[0634] In certain embodiments, R4 is selected from H, Br, -CH3,

[0635] In certain embodiments, R5 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, or optionally substituted C1-C6 alkoxy.

[0636] In certain embodiments, R5 is selected from hydrogen or unsubstituted alkyl.

[0637] In certain embodiments, R5 is selected from hydrogen or unsubstituted C1-C6 alkyl.

[0638] In certain embodiments, R5 is selected from hydrogen or methyl.

[0639] In certain embodiments, R6 is selected from a chemical bond or an optionally substituted C1-C 12 Alkylene.

[0640] In certain embodiments, R6 is selected from a bond, an unsubstituted alkylene group, or an optionally substituted alkylene group.

[0641] In certain embodiments, R6 is selected from a chemical bond, an unsubstituted C1-C 12 Alkylene or optionally substituted C1-C6 alkyl substituted C1-C 12 Alkylene.

[0642] In certain embodiments, R6 is selected from a bond, -CH2-, -CH2CH2-, or -CH(CH3)-.

[0643] In certain embodiments, R7 is selected from optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C 15 Cycloalkyl, optionally substituted C3-C 12 Heterocyclic group, optionally substituted C5-C 12 Aryl or optionally substituted C1-C 17 Heteroaryl.

[0644] In certain embodiments, R7 is selected from optionally substituted aryl-substituted alkyl, alkenyl, optionally substituted aryl-substituted alkenyl, optionally substituted aryl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted aryl-substituted aryl, optionally substituted heteroaryl-substituted aryl, optionally substituted aryloxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted aryl-substituted heteroaryl.

[0645] In certain embodiments, R7 is selected from optionally substituted C5-C 12 Aryl-substituted C1-C6 alkyl, C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl-substituted C2-C6 alkynyl, unsubstituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C3-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryl-substituted C5-C 12 Aryl, optionally substituted C1-C 17 Heteroaryl-substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryloxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted C5-C 12 Aryl-substituted C1-C17 Heteroaryl.

[0646] In certain embodiments, R7 is selected from optionally substituted phenyl-substituted alkyl, alkenyl, optionally substituted phenyl-substituted alkenyl, optionally substituted phenyl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted phenyl-substituted aryl, optionally substituted pyridyl-substituted aryl, optionally substituted phenoxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted phenyl-substituted heteroaryl.

[0647] In certain embodiments, R7 is selected from the group consisting of optionally substituted phenyl-substituted C1-C6 alkyl, C2-C6 alkenyl, optionally substituted phenyl-substituted C2-C6 alkenyl, optionally substituted phenyl-substituted C2-C6 alkynyl, unsubstituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted phenyl substituted C5-C 12 Aryl, optionally substituted pyridyl substituted C5-C 12 Aryl, optionally substituted phenoxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted phenyl substituted C1-C 17 Heteroaryl.

[0648] In certain embodiments, R7 is selected from optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkenyl, optionally substituted C5-C 12 Aryl substituted C2-C6 alkynyl, optionally substituted C3-C 15 Cycloalkyl, unsubstituted C5-C 12 Aryl, halogen-substituted C5-C 12 Aryl, nitro substituted C5-C 12 C5-C substituted with aryl or boronic acid 12 Aryl, optionally substituted C1-C6 alkyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkenyl substituted C5-C 12 Aryl, optionally substituted C2-C6 alkynyl substituted C5-C 12 Aryl, optionally substituted C1-C6 alkoxy substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryl-substituted C5-C 12 Aryl, optionally substituted C1-C 17 Heteroaryl-substituted C5-C 12 Aryl, optionally substituted C5-C 12 Aryloxy substituted C5-C 12 Aryl, unsubstituted C1-C 17 Heteroaryl, halogen-substituted C1-C 17 Heteroaryl, cyano substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkyl substituted C1-C 17 Heteroaryl, optionally substituted C1-C6 alkoxy substituted C1-C 17 Heteroaryl or optionally substituted C5-C 12 Aryl-substituted C1-C 17 Heteroaryl.

[0649] In certain embodiments, R is selected from methyl substituted by fluorophenyl, vinyl, vinyl substituted by methoxycarbonyl, propenyl substituted by methoxycarbonyl, propenyl substituted by phenyl, propynyl substituted by phenyl, cyclopentyl, fluoro substituted phenyl, chloro substituted phenyl, bromo substituted phenyl, nitro substituted phenyl, ethyl substituted phenyl, isopropyl substituted phenyl, vinyl substituted phenyl, ethynyl substituted phenyl, cyclopropylethynyl substituted phenyl, triethylsilylethynyl substituted phenyl, phenylethynyl substituted phenyl, propynyl substituted phenyl, aminopropynyl substituted phenyl, dimethylaminopropynyl substituted phenyl, methylbutynyl substituted phenyl, tert-butoxycarbonylaminopropynyl substituted phenyl, methoxy-substituted phenyl, dimethoxy-substituted phenyl, trimethoxy-substituted phenyl, phenoxy-substituted phenyl, boronic acid-substituted phenyl, biphenyl, pyridyl-substituted phenyl, naphthyl, bromo-substituted naphthyl, methyl-substituted naphthyl, isoquinolyl, cyano-substituted thienyl, fluorine-substituted pyridyl, isopropyl-substituted pyridyl, trifluoromethyl-substituted pyridyl, methoxy-substituted pyridyl, cyano-substituted pyridyl, phenyl-substituted pyridyl, trifluoromethyl-substituted thiazolyl or benzo[d][1,3]dioxolyl.

[0650] In certain embodiments, R7 is selected from vinyl,

[0651] In certain embodiments, X is selected from CH.

[0652] In certain embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from:

[0653] 7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0654] 2-((7-([1,1'-biphenyl]-4-ylmethyl)-3-amino-7H-pyrrolo[3,2-f]quinazolin-1-yl)amino)ethan-1-ol;

[0655] 7-(3-phenylpropyl-2-yn-1-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0656] 7-cinnamyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0657] 7-(3-phenoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0658] 7-(4-ethynylbenzyl)-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0659] (Z)-2-cyano-1-(1-(4-ethynylbenzyl)-2-methyl-1H-benzimidazol-5-yl)guanidine;

[0660] 7-(4-isopropylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0661] N 3 -cyclopropyl-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0662] 7-(4-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0663] 7-(Cyclopentylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0664] 7-(3-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0665] 7-(3,4-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0666] 7-(3,5-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0667] 7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0668] tert-Butyl (3-(4-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)prop-2-yn-1-yl)carbamate;

[0669] N 3 -cyclopropyl-7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0670] N 3 -cyclopropyl-7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0671] N 3 -cyclopropyl-7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0672] N 3-cyclopropyl-7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0673] 7-(4-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0674] 7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0675] 7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0676] 7-(4-(3-aminopropyl-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0677] 7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0678] 7-(Naphth-2-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0679] N 1,7 -bis(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0680] N 1,7 -bis(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0681] N 1 -(4-iodobenzyl)-7-(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0682] 7-(4-ethynylbenzyl)-N 1 -(4-iodobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0683] 7-(4-Ethylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0684] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile;

[0685] 7-(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0686] N 1,7 -bis(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0687] 7-(4-nitrobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0688] 7-allyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0689] 7-(1-(4-fluorophenyl)ethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0690] 7-(Naphthalen-1-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0691] 7-(Quinolin-8-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0692] 7-(4-Fluorophenylethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0693] 7-(4-Fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0694] 7-(4-Fluorobenzyl)-5-(4-methoxyphenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0695] 7-(4-methylnaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0696] 7-(4-Fluorobenzyl)-5-(pyridin-3-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0697] 7-(4-bromonaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0698] 7-((6-fluoropyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0699] 5-Bromo-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0700] 5-Bromo-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0701] 7-((6-fluoropyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0702] 5-cyclopropyl-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0703] 7-((6-(trifluoromethyl)pyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0704] (4-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)boronic acid;

[0705] 7-(4-Fluorobenzyl)-5-(4-fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0706] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)nicotinonitrile;

[0707] Methyl 2-((1,3-diamino-5-bromo-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate;

[0708] 7-(4-Fluorobenzyl)-5-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0709] 7-((2-fluoropyridin-4-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0710] 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile;

[0711] 7-((5-phenylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0712] 7-((5-isopropylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0713] 7-(2-(trifluoromethyl)thiazol-5-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0714] 7-(4-(pyridin-2-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0715] Methyl 2-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate;

[0716] 7-(4-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0717] N 7 -(4-fluorobenzyl)quinazoline-2,4,7-triamine;

[0718] 7-(2-chloro-4-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0719] 7-(3,5-dimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0720] 7-(6-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0721] 7-(2,3-Dichlorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0722] 7-(Benzo[d][1,3]dioxol-5-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine;

[0723] 7-(5-bromo-2-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; and

[0724] 7-(3,4,5-Trimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

[0725] Pharmaceutical composition

[0726] In certain embodiments, the pharmaceutical composition comprises a compound represented by formula (I) of the present disclosure or a pharmaceutically acceptable salt thereof, or a compound of the present disclosure or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0727] In certain embodiments, the compound of the present invention represented by general formula (I) or its pharmaceutically acceptable salt, or the compound of the present invention or its pharmaceutically acceptable salt for preventing or treating tuberculosis (TB) when administered to a mammal can be administered by an enteral route or a parenteral route.

[0728] In certain embodiments, the compound of the present invention represented by general formula (I) or its pharmaceutically acceptable salt, or the compound of the present invention or its pharmaceutically acceptable salt for preventing or treating tuberculosis (TB) when administered to a mammal can be administered orally.

[0729] In certain embodiments, the compound of the present invention represented by general formula (I) or its pharmaceutically acceptable salt, or the compound of the present invention or its pharmaceutically acceptable salt for preventing or treating tuberculosis (TB) when administered to a mammal can be administered via the rectal route.

[0730] The compounds described in the present disclosure can be obtained in any suitable form, such as tablets, capsules, powders, oral solutions, suspensions, rectal gels, rectal foams, rectal enemas or rectal suppositories, etc. Illustrative examples of the tablets include, but are not limited to, plain tablets, sugar-coated tablets, and film-coated tablets.

[0731] Examples of pharmaceutically acceptable excipients that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, any adjuvants, carriers, excipients, glidants, sweeteners, diluents, preservatives, dyes / colorants, flavor enhancers, surfactants, wetting agents, dispersants, suspending agents, stabilizers, isotonic agents, solvents or emulsifiers approved by the U.S. Food and Drug Administration for use in humans or animals, and any carriers that have no side effects on the composition of the pharmaceutical composition. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field and are described, for example, in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990), which is incorporated herein by reference in its entirety.

[0732] The pharmaceutical composition of the present disclosure can be applied by any method that realizes its intended purpose.For example, application can be carried out by oral, parenteral, topical, enteral, intravenous, intramuscular, inhalation, nasal, intraarticular, intraspinal, transtracheal, per ocular, subcutaneous, intraperitoneal, transdermal or buccal routes.The route of administration can be parenteral, oral and rectal routes.The dosage applied will depend on the age, health status and weight of the recipient, and if concurrent treatment is provided, also depends on the type of concurrent treatment, the frequency of treatment, and the nature of the desired effect.

[0733] Suitable dosage forms include, but are not limited to, capsules, tablets, pills, dragees, semisolid preparations, powders, granules, suppositories, ointments, creams, lotions, inhalants, injections, poultices, gels, tapes, eye drops, solutions, syrups, aerosols, suspensions, and emulsions, which can be prepared according to methods known in the art.

[0734] Particularly suitable for oral administration are ordinary tablets (plain tablets), sugar-coated tablets, film-coated tablets, pills, capsules, powders, granules, syrups, juices or drops, suitable for rectal administration are suppositories, suitable for parenteral administration are solutions, also can be oil-based solutions or aqueous solutions, in addition there are also suspensions, emulsions or implants, suitable for topical use are ointments, creams or powders. The product in the present disclosure can also be lyophilized, and the lyophilized material generated is used for example to prepare injections. The given preparation can be sterilized and / or comprise adjuvants (assistant), such as wetting agents, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for changing osmotic pressure, buffer substances, dyes, flavorings and / or numerous other active ingredients, such as one or more vitamins.

[0735] In certain embodiments, the pharmaceutical compositions of the present disclosure are prepared as tablets, solutions, granules, patches, ointments, capsules, aerosols, or suppositories for parenteral, transdermal, mucosal, nasal, buccal, sublingual, or oral use.

[0736] Preservatives, stabilizers, dyes, sweeteners, aromatics, spices, etc. can be provided in the pharmaceutical composition. For example, sodium benzoate, ascorbic acid, and esters of p-hydroxybenzoic acid can be added as preservatives. In addition, antioxidants and suspending agents can be used.

[0737] In different embodiments, alcohols, esters, sulfated aliphatic alcohols, etc. can be used as surfactants; sucrose, glucose, lactose, starch, crystalline cellulose, mannitol, light anhydrous silicate, magnesium aluminate, magnesium aluminate methyl silicate, synthetic aluminum silicate, calcium carbonate, calcium bicarbonate, calcium hydrogen phosphate, hydroxymethylcellulose calcium, etc. can be used as excipients; magnesium stearate, talc, hardened oil, etc. can be used as lubricants; coconut oil, olive oil, sesame oil, peanut oil, soybean can be used as suspending agents or lubricants; cellulose acetate phthalate, which is a derivative of sugars such as cellulose or sugar, or methyl acetate-methacrylate copolymer, which is a derivative of polyethylene, can be used as a suspending agent; and plasticizers such as phthalates can be used as suspending agents.

[0738] Suitable routes of administration may include, for example, oral administration, rectal administration, transmembrane administration, parenteral delivery, topical administration or enteral administration; parenteral delivery includes intramuscular injection, subcutaneous injection, intravenous injection, intramedullary injection and intrathecal injection, direct intraventricular injection, intraperitoneal injection, intranasal injection or intraocular injection. The compound can also be extended and / or timed, pulsed at a predetermined rate in a sustained-release or controlled-release dosage form including depot injections, osmotic pumps, pills, transdermal (including electrotransport) patches, etc.

[0739] The pharmaceutical compositions of the present disclosure can be manufactured in a known manner, for example, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tableting operations.

[0740] Therefore, according to the present disclosure, the pharmaceutical composition used can be prepared in a conventional manner using one or more physiologically acceptable carriers comprising excipients and adjuvants that facilitate processing of the active compound into a pharmaceutically useful preparation. Suitable formulations depend on the selected route of administration. Any known techniques, carriers, and excipients can be used as is suitable and understood in the art.

[0741] Injection can be prepared into the following conventional forms: as a solution or suspension, a solid dosage form suitable for making a solution or suspension before injection, or as an emulsion. Suitable excipients are, for example, water, saline, glucose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine ​​hydrochloride, etc. In addition, if necessary, the injection pharmaceutical composition can contain a small amount of non-toxic adjuvants, such as wetting agents, pH buffers, etc. Physiologically suitable buffers include but are not limited to Hank's solution, Ringer's solution, or physiological saline buffer. If necessary, absorption enhancing preparations (such as liposomes) can be used.

[0742] For oral administration, the compounds can be readily formulated by combining the active compound with a pharmaceutically acceptable carrier known in the art. Such carriers enable the compounds of the present disclosure to be formulated as tablets, pills, lozenges, capsules, liquids, gels, syrups, pastes, suspensions, solutions, powders, and the like for oral ingestion by the patient to be treated. Pharmaceutical preparations for oral administration can be obtained by mixing the active compound with a solid excipient, optionally grinding the resulting mixture, and processing the granular mixture, if necessary, after adding suitable adjuvants, to obtain tablets or lozenge cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidone (PVP). Disintegrants such as cross-linked polyvinylpyrrolidone, agar, or alginic acid or alginates such as sodium alginate may be added if necessary. The dragee core is carried out to suitable coating.For this purpose, concentrated sugar solution can be used, and this sugar solution can optionally comprise gum arabic, talcum, polyvinyl pyrrolidone, carbopol gel (carbopol gel), polyethylene glycol and / or titanium dioxide, lacquer solution and suitable organic solvent or solvent mixture.In order to identify or characterize the different combinations of active compound dosage, dyestuff or pigment can be added in tablet or dragee coating.For this purpose, concentrated sugar solution can be used, and this sugar solution can optionally comprise gum arabic, talcum, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol and / or titanium dioxide, lacquer solution and suitable organic solvent or solvent mixture.

[0743] Pharmaceutical formulations that can be used orally include push-fit capsules made of gelatin and soft, sealed capsules made of gelatin and plasticizers such as glycerol or sorbitol. Push-fit capsules can contain the active ingredient mixed with a filler such as lactose, a binder such as starch, and / or a lubricant such as talc or magnesium stearate, and optionally a stabilizer. In soft capsules, the active ingredient can be dissolved or suspended in a suitable liquid, such as a fatty oil, liquid paraffin, or liquid polyethylene glycol. In addition, a stabilizer can be added. All formulations for oral administration should be in a dosage suitable for such administration.

[0744] In certain embodiments, the pharmaceutical compositions of the present disclosure may contain 0.1%-95% of a compound of the present disclosure or a pharmaceutically acceptable salt thereof.

[0745] In certain embodiments, the pharmaceutical compositions of the present disclosure may contain 1%-70% of a compound of the present disclosure or a pharmaceutically acceptable salt thereof.

[0746] In any case, the composition or formulation to be administered will contain an amount of a compound of the present disclosure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, that is effective to treat the disease / condition in the subject being treated.

[0747] Dosage

[0748] At least one compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising at least one compound of the present disclosure, or a pharmaceutically acceptable salt thereof, can be administered to a patient by any method suitable for systemic and / or local delivery of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof. Non-limiting examples of methods of administration include (a) oral administration, including administration in the form of capsules, tablets, granules, sprays, syrups or other such forms; (b) non-oral administration, such as rectal, vaginal, intraurethral, ​​intraocular, intranasal or intraaural, including administration in the form of aqueous suspensions, oily preparations, etc. or in the form of drops, sprays, suppositories, ointments, ointments, etc.; (c) administration by subcutaneous injection, intraperitoneal injection, intravenous injection, intramuscular injection, intradermal injection, intraorbital injection, intracapsular injection, intraspinal injection, intrasternal injection, etc., including delivery by infusion pump; (d) local administration, such as injection directly in the renal area or cardiac area, for example, by reservoir implantation; and (e) topical administration; as deemed appropriate by those skilled in the art, the compound described in the present disclosure is in contact with living tissue.

[0749] The most suitable route depends on the nature and severity of the disease state being treated. Those skilled in the art are also familiar with determining the method of administration (oral, intravenous, inhalation, subcutaneous, rectal, etc.), dosage form, appropriate pharmaceutical excipients and other matters related to delivering the compound, its stereoisomer or its pharmaceutically acceptable salt to a subject in need.

[0750] Pharmaceutical compositions suitable for administration include compositions containing an effective amount of an active ingredient to achieve their desired effect. The dosage required for a therapeutically effective amount of the pharmaceutical compositions described in this disclosure depends on the route of administration, the type of animal being treated, including humans, and the physical characteristics of the particular animal being considered. The dosage can be adjusted to achieve the desired effect, but this will depend on factors such as body weight, diet, concurrent medications, and other factors recognized by those skilled in the art of medicine. More specifically, a therapeutically effective amount refers to an amount of a compound that effectively prevents, alleviates, or ameliorates symptoms of a disease, or prolongs the lifespan of the individual being treated. A therapeutically effective amount is well within the skill of those skilled in the art, particularly in light of the detailed disclosure provided herein.

[0751] As will be apparent to those skilled in the art, the dosage and specific mode of administration for in vivo administration will vary depending on the age, weight, and type of mammal being treated, the specific compound being used, and the specific purpose of the compound being used. Conventional pharmacological methods can be used by those skilled in the art to determine effective dosage levels, i.e., dosage levels necessary for the desired effect. Typically, clinical use of the product in humans is initiated at lower dosage levels, with the dosage levels increasing until the desired effect is achieved. Alternatively, using established pharmacological methods, acceptable in vitro studies can be used to establish effective dosages and routes of administration for the compositions identified by the present method.

[0752] In non-human animal studies, the use of potential products is initiated at higher dose levels, with the dose being reduced until the desired effect is no longer achieved or the adverse side effects disappear. Depending on the desired effect and the therapeutic indication, the dosage range can be relatively wide. Typically, the dosage can be from about 10 μg / kg body weight to 1000 mg / kg body weight, and in certain embodiments, from about 100 μg / kg body weight to 300 mg / kg body weight. Alternatively, as will be appreciated by those skilled in the art, the dosage can be based on and calculated according to the patient's body surface area.

[0753] Each physician will be able to select the exact formulation, route of administration, and dosage of the pharmaceutical compositions described herein based on the patient's condition. Typically, the composition administered to a patient may be administered in a dosage range of about 0.5 mg / kg to 1000 mg / kg of the patient's body weight. Depending on the patient's needs, the dosage may be administered once alone or twice or more frequently over a day or several days. In cases where human dosages for a compound have been established for at least some conditions, the present disclosure will use those same dosages, or dosages ranging from about 0.1% to 500% of the established human dosage, and in certain embodiments, from 25% to 250% of the established human dosage. In cases where there is no established human dosage, such as in the case of a newly discovered pharmaceutical compound, an appropriate human dosage can be inferred from the median effective dose or infective dose, or other appropriate values ​​from in vitro or in vivo studies, as quantified in animal toxicity studies and efficacy studies.

[0754] It should be noted that due to toxicity and organ dysfunction, the attending physician will know how and when to terminate, interrupt or adjust the administration. On the contrary, if the clinical response is insufficient (excluding toxicity), the attending physician will also know to adjust the treatment to a higher level. The size of the dosage in the treatment of the disease being paid attention to will change with the severity of the disease state to be treated and the change of the route of administration. For example, the severity of the disease state can be evaluated in part by a standard prognostic evaluation method. In addition, the dosage and possible dosage frequency will also change according to the age, body weight, and reaction of the individual patient. A scheme comparable to the above-mentioned discussion scheme can be used in veterinary medicine.

[0755] Although the exact dosage can be determined based on a drug-by-drug analysis, in most cases, it is possible to make certain generalizations about the medicament. The daily dosing regimen for adult patients is, for example, an oral dose of 0.1 mg to 2000 mg of each active ingredient, in certain embodiments 1 mg to 2000 mg of each active ingredient, for example 5 mg to 1500 mg of each active ingredient. In other embodiments, the intravenous, subcutaneous or intramuscular dose of each active ingredient used is 0.01 mg to 1000 mg, in certain embodiments 0.1 mg to 1000 mg, for example 1 mg to 800 mg. In the case of administering a pharmaceutically acceptable salt, the dosage can be calculated as the free base. In certain embodiments, the composition is administered 1 to 4 times daily. Alternatively, the composition described in the present disclosure can be administered by continuous intravenous infusion, in certain embodiments administered at a dosage of up to 2000 mg of each active ingredient per day. As will be appreciated by those skilled in the art, in some cases, it may be necessary to administer the compounds described herein in amounts exceeding or far exceeding the above dosage ranges in order to effectively and rapidly treat rapidly developing diseases or infections. In certain embodiments, the compounds are administered over a continuous treatment period, such as one or several weeks, or several months or years.

[0756] Dosage and dosing interval can be adjusted individually to provide a plasma level of the active moiety sufficient to maintain the adjustment effect or minimum effective concentration (MEC). The MEC of each compound is different, but it is possible to estimate the MEC from in vitro data. The required dosage to reach the MEC depends on individual characteristics and route of administration. However, plasma concentration can be determined using HPLC (high performance liquid chromatography) assays or bioassays.

[0757] Dosage intervals can also be determined using the MEC. Compositions should be administered using a regimen that maintains plasma levels above the MEC for 10-90% of the time, in certain embodiments 30-90% of the time, and in certain embodiments 50-90% of the time.

[0758] In cases of local administration or selective uptake, the effective local concentration of the drug is independent of plasma concentration.

[0759] The amount of composition administered will, of course, be dependent on the individual being treated, on the individual's weight, the severity of the affliction, the manner of administration, and the judgment of the prescribing physician.

[0760] The efficacy and toxicity of the compounds described herein can be assessed using known methods. For example, the toxicology of a specific compound, or a subset of compounds sharing certain chemical moieties, can be established by in vitro toxicity assays in cell lines, such as mammalian cell lines, and in certain embodiments, human cell lines. The results of such studies are generally predictive of toxicity in animals such as mammals, or more specifically, in humans. Alternatively, the toxicity of a specific compound can be assessed in animal models such as mice, rats, rabbits, or monkeys using known methods. The efficacy of a specific compound can be determined using several recognized methods, such as in vitro methods, animal models, or human clinical trials. Recognized in vitro models exist for nearly every disease state, including but not limited to cancer, cardiovascular disease, and various immune disorders. Similarly, acceptable animal models can be used to determine the efficacy of chemical agents used to treat these disease states. When selecting a model to determine efficacy, the skilled artisan can select an appropriate model, dosage, route of administration, and treatment regimen, guided by existing knowledge in the art. Of course, human clinical trials can also be used to determine the efficacy of a compound in humans.

[0761] If desired, the composition can be placed in a package or dispensing device that can contain one or more unit dosage forms containing the active ingredient. The package can, for example, include metal or plastic foil, such as a blister pack. The package or dispensing device can carry instructions for administration. The package or dispensing device can also carry notes associated with the container, which are prescribed by a government agency that manages drug production, use, or sales, reflecting that the drug form has been approved by the agency for human or veterinary administration. Such notes, for example, can be a label approved for prescription drugs by the State Food and Drug Administration or the U.S. Food and Drug Administration, or an approved product instruction sheet. Compositions comprising a compound of the present disclosure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, can also be prepared in a suitable container and placed in a compatible pharmaceutical carrier and labeled for use in the treatment of a specified disease state.

[0762] Hereinafter, the present disclosure will be explained in detail through the following examples in order to better understand the various aspects and advantages of the present application. However, it should be understood that the following examples are non-limiting and are only used to illustrate certain embodiments of the present disclosure.

[0763] Example

[0764] The reagents and equipment used in the examples of this disclosure are conventional and commercially available.

[0765] For example:

[0766] Preparation Example

[0767] The compounds were prepared according to the following general reaction scheme. Common solvents were purified before use. All reagents were reagent grade and purified as necessary. Reactions were monitored by thin layer chromatography (TLC) using Whatman pre-coated silica gel plates. Flash column chromatography was performed on ultrapure silica gel (200 to 400 mesh) from Merck. Spectrometers were recorded on a Bruker AVANCE 300 (300 MHz), 400 MHz, or 500 MHz spectrometer. 1 H NMR spectrum. 1 H NMR multiplicities are designated as s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, dd = doublet of doublet, dt = doublet of triplet, m = multiplet, br = broad. Electrospray impact (ESI) mass spectra were recorded on an ISQEC mass spectrometer.

[0768] To a stirred solution of 7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (1.0 mmol) in dry DMF (20 mL) was added NaH (1.2 mmol). The resulting reaction mixture was stirred at 0°C for 0.5 hours. The corresponding bromide (1.5 mmol) was then added. The reaction mixture was stirred at 0°C for 1 hour. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel using 10:1 DCM:MeOH containing 1% Et3N to give the desired compound as a solid.

[0769] Compound 1

[0770] 1H NMR (500MHz, DMSO-d6) δ7.71(d,J=9.0Hz,1H),7.62(d,J=3.0Hz,1H),7.41(d,J=8.0Hz,2H),7.15(d,J=8.0 Hz,2H),7.12(d,J=3.0Hz,1H),7.03(d,J=9.0Hz,1H),6.78(s,2H),5.89(s,2H),5.53(s,2H),4.14(s,1H).

[0771] MS(ESI):[M+H + ]314.12

[0772] Compound 2

[0773] 1 H NMR (400MHz, DMSO-d6) δ7.92(d,J=9.0Hz,1H),7.85(d,J=3.2Hz,1H),7.65-7.56(m,5H),7.47-7.40(m,2H ),7.37-7.31(m,1H),7.29-7.24(m,2H),7.22-7.11(m,2H),6.74(s,2H),5.60(s,2H),3.84-3.66(m,4H).

[0774] MS(ESI):[M+H + ]410.18

[0775] Compound 3

[0776] 1 H NMR (300MHz, DMSO-d6) δ7.88(d,J=9.0Hz,1H),7.58(d,J=3.3Hz,1H),7.46-7.33(m,5H),7.17-7.06(m,2H),6.70(s,2H),5.72(s,2H),5.43(s,2H).

[0777] MS(ESI):[M+H + ]314.12

[0778] Compound 4

[0779] 1H NMR(300MHz, DMSO-d6)δ7.80(d,J=9.0Hz,1H),7.52(d,J=3.0Hz,1H),7.43-7.37(m,2H),7.34-7.26(m,2H),7.26-7.22 (m,1H),7.08(d,J=3.0Hz,1H),7.05(d,J=9.0Hz,1H),6.67(s,2H),6.52-6.46(m,2H),5.67(s,2H),5.09-5.01(m,2H).

[0780] MS(ESI):[M+H + ]316.15

[0781] Compound 5

[0782] 1 H NMR (300MHz, DMSO-d6) δ7.71(d,J=9.0Hz,1H),7.60(d,J=3.0Hz,1H),7.39-7.25(m,3H),7.13(d,J=7.2Hz,1H),7.08( d,J=3.0Hz,1H),7.02(d,J=9.0Hz,1H),6.97-6.89(m,3H),6.87-6.80(m,2H),6.68(s,2H),5.69(s,2H),5.50(s,2H).

[0783] MS(ESI):[M+H + ]382.12

[0784] Compound 6

[0785] 1 H NMR (400MHz, DMSO-d6) δ7.98(d,J=6.9Hz,1H),7.88(d,J=7.6Hz,1H),7.80(dd,J=6.9,0.6Hz,1H),7.64(d,J=7.8Hz,1H), 7.42-7.34(m,2H),7.14(dt,J=7.3,1.0Hz,2H),6.71(d,J=0.8Hz,1H),6.59 (d,J=7.6Hz,1H),6.25(d,J=7.6Hz,1H),5.43(t,J=1.0Hz,2H),4.22(s,1H).

[0786] MS(ESI):[M+H + ]328.39

[0787] Compound 7

[0788] 1 H NMR(400MHz, DMSO-d6) δ 8.93 (s, 1H), 7.52 - 7.46 (m, 1H), 7.42 - 7.34 (m, 2H), 7.21 (dd, J = 1.9, 0.6 Hz, 1H), 7.14 (dt, J = 7.3, 1.1 Hz, 2H), 6.82 (d, J = 6.4 Hz, 1H), 6.65 - 6.57 (m, 2H), 5.31 (t, J = 1.0 Hz, 2H).

[0789] MS(ESI): [M + H + 329.42

[0790] Compound 8

[0791] 1 H NMR(500MHz, DMSO-d6) δ 7.73 (d, J = 9.0 Hz, 1H), 7.59 (d, J = 3.0 Hz, 1H), 7.15 (d, J = 8.0 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 7.06 (d, J = 3.0 Hz, 1H), 7.01 (d, J = 8.9 Hz, 1H), 6.65 (s, 2H), 5.65 (s, 2H), 5.43 (s, 2H), 2.80 (p, J = 7.0 Hz, 1H), 1.12 (d, J = 6.9 Hz, 6H).

[0792] MS(ESI): [M + H + 332.42

[0793] Compound 9

[0794] 1 H NMR(300MHz, DMSO-d6) δ 7.70 (d, J = 9.0 Hz, 1H), 7.62 (d, J = 3.0 Hz, 1H), 7.41 (d, J = 8.2 Hz, 2H), 7.14 (d, J = 8.2 Hz, 2H), 7.11 (d, J = 3.0 Hz, 1H), 7.09 (d, J = 9.0 Hz, 1H), 6.68 (s, 2H), 6.47 - 6.30 (m, 1H), 5.53 (s, 2H), 4.16 (s, 1H), 2.84 - 2.70 (m, 1H), 0.68 - 0.57 (m, 2H), 0.48 - 0.39 (m, 2H).

[0795] MS(ESI): [M + H + 354.15

[0796] Compound 10

[0797] 1 H NMR(500MHz,DMSO-d6)δ8.08(d,J=9.0Hz,1H),7.91(d,J=3.0Hz,1H),7.60(s,2H),7.37(d ,J=3.0Hz,1H),7.31-7.24(m,2H),7.21(d,J=9.0Hz,1H),7.18-7.11(m,2H),5.56(s,2H).

[0798] MS(ESI):[M+H + ]308.15

[0799] Compound 11

[0800] 1 H NMR (500MHz, DMSO-d6) δ7.78(d,J=9.0Hz,1H),7.47(d,J=3.0Hz,1H),7.05(d,J=9.0Hz,1H),7. 00(d,J=3.0Hz,1H),6.68(s,2H),5.69(s,2H),4.13(d,J=7.5Hz,2H),2.42-2.29(m,1H),1.66- 1.58(m,2H),1.58-1.52(m,2H),1.51-1.44(m,2H),1.28-1.20(m,2H).

[0801] MS(ESI):[M+H + ]282.24

[0802] Compound 12

[0803] 1 H NMR(400MHz,DMSO-d6)δ7.92-7.82(m,1H),7.80-7.72(m,1H),7.39-7.31(m ,1H),7.25-7.18(m,1H),7.14-7.05(m,2H),7.04-6.96(m,2H),5.55(s,2H).

[0804] MS(ESI):[M+H + ]308.06

[0805] Compound 13

[0806] 1 H NMR (400MHz, DMSO-d6) δ7.75(d,J=9.0Hz,1H),7.63(d,J=3.0Hz,1H),7.41-7.34(m,1H),7.34-7.26(m,1H ),7.11(d,J=3.0Hz,1H),7.03(d,J=9.0Hz,1H),7.02-6.99(m,1H),6.72(s,2H),5.73(s,2H),5.49(s,2H).

[0807] MS(ESI):[M+H + ]326.10

[0808] Compound 14

[0809] 1 H NMR(400MHz,DMSO-d6)δ7.76(d,J=9.0Hz,1H),7.66(d,J=3.2Hz,1H),7.18-7.09(m,2 H),7.05(d,J=9.0Hz,1H),6.90-6.84(m,2H),6.78(s,2H),5.81(s,2H),5.54(s,2H).

[0810] MS(ESI):[M+H + ]326.10

[0811] Compound 15

[0812] 1 H NMR (400MHz, DMSO-d6) δ7.69(d,J=9.0Hz,1H),7.60(d,J=3.2Hz,1H),7.27(d,J=8.0Hz,2H),7.09(d,J=8.0Hz ,3H),7.01(d,J=9.0Hz,1H),6.77(s,2H),5.78(s,2H),5.48(s,2H),2.81-2.65(m,1H),1.15(d,J=6.8Hz,6H).

[0813] MS(ESI):[M+H + ]356.20

[0814] Compound 16

[0815] 1H NMR (500MHz, DMSO-d6) δ7.70(d,J=9.0Hz,1H),7.61(d,J=3.1Hz,1H),7.34-7.29(m,2H),7.29(s,1H),7.18-7.05(m,3H),7.01 (d,J=9.0Hz,1H),6.79(s,2H),5.79(s,2H),5.49(s,2H),3.91(d,J=6.0Hz,2H),1.35(s,9H).

[0816] MS(ESI):[M+H + ]443.53

[0817] Compound 17

[0818] 1 H NMR(400MHz,DMSO-d6)δ7.68(m,1H),7.64-7.59(m,1H),7.34-7.26(m,2H),7.15-7.06(m,4H),6.67(s,2 H),6.37(s,1H),5.51(s,2H),2.83-2.74(m,1H),1.18(d,J=6.9Hz,6H),0.63(m,2H),0.51-0.37(m,2H).

[0819] MS(ESI):[M+H + ]396.50

[0820] Compound 18

[0821] 1 H NMR(400MHz,DMSO-d6)δ7.73(d,J=9.2Hz,1H),7.69-7.60(m,1H),7.32(d,J=6.4Hz,2H),7.15-7 .07(m,4H),5.51(s,2H),2.88-2.72(m,1H),0.86(t,J=6.4Hz,2H),0.64(dd,J=6.4,2.4Hz,2H).

[0822] MS(ESI):[M+H + ]368.45

[0823] Compound 19

[0824] 1H NMR (400MHz, DMSO-d6) δ7.74(d,J=8.8Hz,1H),7.66(d,J=3.2Hz,1H),7.55-7.49(m,4H),7.42(d,J=3.2Hz,3H),7.20(d ,J=8.0Hz,2H),7.15-7.11(m,2H),6.75(s,2H),6.46(s,1H),5.57(s,2H),2.79(m,1H),0.64(m,2H),0.52-0.40(m,2H).

[0825] MS(ESI):[M+H + ]430.49

[0826] Compound 20

[0827] 1 H NMR (400MHz, DMSO-d6) δ7.71(d,J=9.2Hz,1H),7.61(d,J=3.2Hz,1H),7.33-7.26(m,2H),7.16-7.06(m,4H ),6.69(s,2H),6.40(s,1H),5.50(s,2H),2.79(m,1H),1.51(m,1H),0.91-0.81(m,4H),0.73-0.59(m,4H)

[0828] MS(ESI):[M+H + ]394.19

[0829] Compound 21

[0830] 1 H NMR (400MHz, DMSO-d6) δ7.98(d,J=6.9Hz,1H),7.88(d,J=7.6Hz,1H),7.80(dd,J=6.9,0.6Hz,1H),7.64(d,J=7.8Hz,1H),7.43-7.34( m,3H),7.14(dt,J=6.9,1.0Hz,2H),7.01(dd,J=5.0,0.6Hz,1H),6.59(d,J=7.6Hz,1H),6.25(d,J=7.6Hz,1H),5.38(t,J=1.0Hz,2H).

[0831] MS(ESI):[M+H + ]371.45

[0832] Compound 22

[0833] 1 H NMR (400MHz, DMSO-d6) δ7.70(d,J=8.8Hz,1H),7.61(d,J=3.2Hz,1H),7.29(d,J=8.0Hz,2H),7.17-7.08(m,3H),7 .02(d,J=8.8Hz,1H),6.73(s,2H),5.76(s,2H),5.50(s,2H),1.50(m,1H),0.91-0.79(m,2H),0.72-0.64(m,2H).

[0834] MS(ESI):[M+H + ]354.46

[0835] Compound 23

[0836] 1 H NMR(400MHz,DMSO-d6)δ7.80(d,J=8.8Hz,1H),7.71(d,J=3.2Hz,1H),7.57-7.46(m,4H),7 .42(q,J=2.8Hz,3H),7.25-7.16(m,3H),7.08(d,J=8.8Hz,1H),6.13(s,2H),5.58(s,2H).

[0837] MS(ESI):[M+H + ]390.41

[0838] Compound 24

[0839] 1 H NMR(400MHz,DMSO-d6)δ8.06(d,J=9.0Hz,1H),7.93(d,J=3.2Hz,1H),7.67(s, 2H),7.47-7.37(m,3H),7.22(dd,J=9.0,2.4Hz,3H),5.64(s,2H),3.98(s,2H).

[0840] MS(ESI):[M+H + ]343.38

[0841] Compound 25

[0842] 1H NMR(400MHz, DMSO-d6)δ7.75(d,J=9.0Hz,1H),7.65(d,J=3.2Hz,1H),7.37-7.26(m,2H),7. 17-7.10(m,3H),7.04(d,J=9.0Hz,1H),6.88(s,2H),5.93(s,2H),5.51(s,2H),2.00(s,3H).

[0843] MS(ESI):[M+H + ]328.37

[0844] Compound 26

[0845] 1 H NMR(300MHz,DMSO-d6)δ7.90-7.79(m,4H),7.77(d,J=3.2Hz,1H),7.72(s,1H),7.52-7.43(m,2H),7 .33(dd,J=8.5,1.8Hz,1H),7.19(d,J=3.2Hz,1H),7.06(d,J=9.0Hz,1H),6.22(s,2H),5.68(s,2H).

[0846] MS(ESI):[M+H + ]340.35

[0847] Compound 27

[0848] 1 H NMR(500MHz,DMSO-d6)δ7.70(s,1H),7.65(d,J=3.5Hz,1H),7.41-7.34(m,6H),7.31(s,1H),7.23(d,J=3.0H z,1H),7.14(d,J=8.0Hz,2H),5.86(s,2H),5.51(s,2H),4.83(d,J=6.0Hz,2H),0.95(m,18H),0.59(m,12H).

[0849] MS(ESI):[M+H + ]657.03

[0850] Compound 28

[0851] 11H NMR (400 MHz, DMSO-d6) δ 8.01 - 7.91 (m, 2H), 7.80 (dd, J = 6.9, 0.6 Hz, 1H), 7.50 - 7.43 (m, 2H), 7.43 - 7.34 (m, 3H), 7.28 (dt, J = 8.2, 1.0 Hz, 2H), 7.14 (dt, J = 7.3, 1.0 Hz, 2H), 7.01 (dd, J = 5.0, 0.6 Hz, 1H), 6.59 (d, J = 7.6 Hz, 1H), 6.25 (d, J = 7.6 Hz, 1H), 5.38 (t, J = 1.0 Hz, 2H), 4.71 (dt, J = 5.3, 1.0 Hz, 2H).

[0852] MS (ESI): [M+H + 428.52

[0853] Compound 29

[0854] 1 1H NMR (400 MHz, DMSO-d6) δ 8.01 - 7.91 (m, 2H), 7.80 (dd, J = 6.9, 0.5 Hz, 1H), 7.67 - 7.59 (m, 2H), 7.43 - 7.35 (m, 3H), 7.14 (dt, J = 6.9, 1.0 Hz, 2H), 7.06 (dt, J = 7.4, 1.0 Hz, 2H), 7.01 (dd, J = 5.0, 0.6 Hz, 1H), 6.59 (d, J = 7.6 Hz, 1H), 6.25 (d, J = 7.6 Hz, 1H), 5.38 (t, J = 1.0 Hz, 2H), 4.71 (dt, J = 5.3, 1.0 Hz, 2H), 0.93 (t, J = 7.3 Hz, 8H), 0.72 - 0.62 (m, 6H).

[0855] MS (ESI): [M+H + 644.71

[0856] Compound 30

[0857] 11H NMR (400 MHz, DMSO-d6) δ 8.01 - 7.91 (m, 2H), 7.80 (dd, J = 6.9, 0.6 Hz, 1H), 7.67 - 7.59 (m, 2H), 7.43 - 7.34 (m, 3H), 7.14 (dt, J = 7.3, 1.0 Hz, 2H), 7.06 (dt, J = 7.4, 1.0 Hz, 2H), 7.01 (dd, J = 5.0, 0.6 Hz, 1H), 6.59 (d, J = 7.6 Hz, 1H), 6.25 (d, J = 7.6 Hz, 1H), 5.38 (t, J = 1.0 Hz, 2H), 4.71 (dt, J = 5.3, 1.0 Hz, 2H).

[0858] MS (ESI): [M+H + 530.29

[0859] Compound 31

[0860] 1 1H NMR (400 MHz, DMSO-d6) δ 7.79 (d, J = 9.0 Hz, 1H), 7.65 (d, J = 3.2 Hz, 1H), 7.13 (t, J = 3.2 Hz, 5H), 7.05 (d, J = 9.0 Hz, 1H), 6.92 (s, 2H), 5.98 (s, 2H), 5.46 (s, 2H), 2.55 (m, 2H), 1.12 (t, J = 7.6 Hz, 3H).

[0861] MS (ESI): [M+H + 318.36

[0862] Compound 32

[0863] 1 1H NMR (400 MHz, DMSO-d6) δ 7.98 (d, J = 6.9 Hz, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.80 (dd, J = 6.9, 0.6 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.41 (d, J = 5.8 Hz, 1H), 7.29 (d, J = 5.0 Hz, 1H), 7.06 (d, J = 5.0 Hz, 1H), 6.83 (d, J = 5.7 Hz, 1H), 6.59 (d, J = 7.6 Hz, 1H), 6.25 (d, J = 7.6 Hz, 1H), 5.38 (s, 2H).

[0864] MS (ESI): [M+H + 321.39

[0865] Compound 33

[0866] 1 H NMR (500MHz, DMSO-d6) δ7.71(d,J=9.0Hz,1H),7.60(d,J=3.0Hz,1H),7.41-7.34(m,2H),7.13(d,J=8.2Hz,2H),7.07(d,J=3.0Hz,1H ),7.00(d,J=9.0Hz,1H),6.74(s,2H),6.65(dd,J=17.6,11.0Hz,1H),5.81-5.68(m,3H),5.46(s,2H),5.19(dd,J=10.9,1.0Hz,1H).

[0867] MS(ESI):[M+H + ]316.40

[0868] Compound 34

[0869] 1 H NMR(400MHz,DMSO-d6)δ8.01-7.91(m,2H),7.80(dd,J=6.9,0.5Hz,1H),7.63-7.55(m ,2H),7.40(d,J=5.1Hz,1H),7.35-7.29(m,2H),7.25(ddt,J=8.9,3.8,1.1Hz,4H),7. 01(dd,J=5.0,0.5Hz,1H),6.72(t,J=10.8Hz,2H),6.59(d,J=7.6Hz,1H),6.25(d,J=7 .6Hz,1H),5.60(d,J=10.9Hz,4H),5.38(t,J=1.0Hz,2H),4.71(dt,J=5.3,1.0Hz,2H).

[0870] MS(ESI):[M+H + ]432.56

[0871] Compound 35

[0872] 1 H NMR (400MHz, DMSO-d6) δ8.22-8.17(m,2H),7.96(d,J=9.0Hz,1H),7.91(d,J=3 .2Hz,1H),7.43-7.35(m,3H),7.19(d,J=9.0Hz,1H),7.12(s,2H),5.76(s,2H).

[0873] MS(ESI):[M+H + ]335.08

[0874] Compound 36

[0875] 1 H NMR (400MHz, DMSO-d6) δ7.98(d,J=6.9Hz,1H),7.88(d,J=7.6Hz,1H),7.83-7.77(m,1H),7.64(d,J=7.8Hz,1H),7.14(d,J=5.3 Hz,1H),7.06(d,J=5.3Hz,1H),6.59(d,J=7.6Hz,1H),6.25(d,J=7.6Hz,1H),6.06(tt,J=10.7,5.3Hz,1H),5.22-5.14(m,4H).

[0876] MS(ESI):[M+H + ]240.23

[0877] Compound 37

[0878] 1 H NMR(400MHz, DMSO-d6)δ7.80(d,J=3.2Hz,1H),7.74(d,J=8.8Hz,1H),7.33-7.23(m,2H),7.19-7.07( m,3H),7.01(d,J=8.8Hz,1H),6.80(s,2H),5.95(q,J=6.8Hz,1H),5.81(s,2H),1.90(d,J=6.8Hz,3H).

[0879] MS(ESI):[M+H + ]322.32

[0880] Compound 28

[0881] 11H NMR (400 MHz, DMSO-d6) δ 8.11 (ddd, J = 7.7, 1.4, 0.7 Hz, 1H), 8.01 - 7.93 (m, 2H), 7.91 - 7.82 (m, 2H), 7.80 (dd, J = 6.9, 0.6 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.61 - 7.53 (m, 1H), 7.55 - 7.43 (m, 2H), 7.43 - 7.35 (m, 2H), 7.01 (dd, J = 5.0, 0.6 Hz, 1H), 6.59 (d, J = 7.6 Hz, 1H), 6.25 (d, J = 7.6 Hz, 1H), 5.87 (s, 2H).

[0882] MS (ESI): [M+H + 340.42

[0883] Compound 39

[0884] 1 1H NMR (400 MHz, DMSO-d6) δ 9.07 (dd, J = 4.0, 2.0 Hz, 1H), 8.43 (dd, J = 8.4, 2.0 Hz, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 3.2 Hz, 1H), 7.65 (dd, J = 8.4, 4.4 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.16 (d, J = 3.2 Hz, 1H), 7.03 (dd, J = 8.4, 4.4 Hz, 2H), 6.92 (s, 2H), 6.15 (s, 2H), 5.95 (s, 2H).

[0885] MS (ESI): [M+H + 341.33

[0886] [[ID=二十一]]Compound 40

[0887] 1 1H NMR (400 MHz, DMSO-d6) δ 7.78 (d, J = 8.8 Hz, 1H), 7.37 (d, J = 3.2 Hz, 1H), 7.25 - 7.14 (m, @@@), 7.12 - 6.94 (m, 4H), 6.73 (s, 2H), 5.79 (s, 2H), 4.47 (t, J = 7.2 Hz, 2H), 3.08 (t, J = 7.2 Hz, 2H).

[0888] MS (ESI): [M+H + 341.33

[0889] Compound 41

[0890] 1 H NMR (300MHz, Methanol-d4) δ7.78 (dd, J=9.1, 0.9Hz, 1H), 7.66 (d, J=3.3Hz, 1H), 7.62-7.55 (m, 2H), 7.41-7.30 (m, 2H), 7.25-7.18 (m, 2H).

[0891] MS(ESI):[M+H + ]294.30

[0892] Compound 42

[0893] 1 H NMR (400MHz, DMSO-d6) δ7.74 (s, 1H), 7.65 (d, J = 3.2Hz, 1H), 7.55-7.46 (m, 2H), 7.30-7.20 (m, 2 H),7.20-7.09(m,3H),7.01-6.94(m,2H),6.83(s,2H),5.71(s,2H),5.54(s,2H),3.80(s,3H).

[0894] MS(ESI):[M+H + ]414.48

[0895] Compound 43

[0896] 1 H NMR (400MHz, DMSO-d6) δ8.22-8.13(m,1H),8.12-8.03(m,1H),7.72(d,J=9.2Hz,1H),7.66-7.57(m,2H),7.48(d,J=3.2Hz,1H),7.2 4(d,J=7.2Hz,1H),7.11(d,J=3.2Hz,1H),7.02(d,J=9.2Hz,1H),6.70(s,2H),6.68(s,1H),5.97(s,2H),5.70(s,2H),2.62(s,3H).

[0897] MS(ESI):[M+H + ]354.44

[0898] Compound 44

[0899] 1H NMR (400MHz, Methanol-d4) δ8.70(dd,J=2.2,0.8Hz,1H),8.57(dd,J=4.8,1.6Hz,1H),8.04(dt,J=8.0,2.0Hz,1H),7.83(d,J=0 .8Hz,1H),7.66(d,J=3.2Hz,1H),7.56(m,1H),7.29-7.18(m,2H),7.13(dd,J=3.2,0.8Hz,1H),7.10-7.00(m,2H),5.56(s,2H).

[0900] MS(ESI):[M+H + ]385.41

[0901] Compound 45

[0902] 1 H NMR (400MHz, DMSO-d6) δ8.25(m,2H),7.79-7.70(m,4H),7.55(d,J=3.1Hz,1H),7.17(d,J=3.1 Hz,1H),7.03(d,J=8.9Hz,1H),6.76(s,2H),6.54(d,J=7.7Hz,1H),6.04(s,2H),5.76(s,2H).

[0903] MS(ESI):[M+H + ]418.31

[0904] Compound 46

[0905] 1 H NMR (400MHz, DMSO-d6) δ8.24(d,J=2.4Hz,1H),7.99(d,J=8.9Hz,1H),7.82(t,J=5.5Hz,2H) ,7.47(s,2H),7.25(d,J=3.2Hz,1H),7.15(dd,J=8.9,2.4Hz,2H),6.58(s,2H),5.59(s,2H).

[0906] MS(ESI):[M+H + ]309.36

[0907] Compound 47

[0908] 1H NMR (400MHz, DMSO-d6) δ8.21(s,1H),7.66(d,J=3.2Hz,1H),7.29-7.20(m,2H),7.20-7.09(m,3H),6.85(s,2H),5.94(s,2H),5.51(s,2H).

[0909] MS(ESI):[M+H + ]386.21

[0910] Compound 48

[0911] 1 H NMR(400MHz,Chloroform-d+MeOD)δ7.82(d,J=1.2Hz,1H),7.30(d,J=8.0Hz,2H),7.25 -7.23(m,1H),6.90(d,J=8.0Hz,2H),6.72(d,J=3.2Hz,1H),5.29(s,2H),3.03(s,1H).

[0912] MS(ESI):[M+H + ]393.25

[0913] Compound 49

[0914] 1 H NMR (400MHz, DMSO-d6) δ8.00-7.86(m,2H),7.77(d,J=3.0Hz,1H),7.65(s,1H),7.29(d,J=3.0Hz,1H),7. 15(d,J=8.8Hz,1H),7.09(dd,J=8.0,2.4Hz,1H),6.95(dd,J=8.0,2.4Hz,1H),6.76(s,2H),5.63(s,2H).

[0915] MS(ESI):[M+H + ]309.33

[0916] Compound 50

[0917] 1 H NMR(400MHz, Methanol-d4)δ7.59(d,J=4.4Hz,2H),7.27-7.15(m,2H),7.13- 6.98(m,3H),5.53(s,2H),2.20(m,1H),1.15-1.03(m,2H),0.76-0.65(m,2H).

[0918] MS(ESI):[M+H + ]348.45

[0919] Compound 51

[0920] 1 H NMR(400MHz,Chloroform-d+MeOD)δ8.35(d,J=2.0Hz,1H),7.45(m 2H),7.35(dd,J=8.4,2.0Hz,1H),7.28(s,1H),7.03(d,J=8.4Hz,1H),6.77(d,J=3.2Hz,1H),5.42(s,2H).

[0921] MS(ESI):[M+H + ]359.30

[0922] Compound 52

[0923] 1 H NMR (400MHz, DMSO-d6) δ8.03(m,3H),7.92(d,J=3.2Hz,1H),7.71(d,J=7.6Hz,2H),7.45( s,2H),7.38(d,J=3.2Hz,1H),7.21(d,J=8.8Hz,1H),7.15(d,J=7.6Hz,2H),5.59(s,2H).

[0924] MS(ESI):[M+H + ]334.17

[0925] Compound 53

[0926] 1 H NMR(400MHz, Methanol-d4)δ7.79(d,J=0.8Hz,1H),7.69(d,J=3.2Hz,1H),7.56-7.44( m,2H),7.30-7.19(m,4H),7.16(dd,J=3.2,0.8Hz,1H),7.10-7.01(m,2H),5.55(s,2H).

[0927] MS(ESI):[M+H + ]402.40

[0928] Compound 54

[0929] 1 H NMR (400MHz, DMSO-d6) δ8.94(d,J=2.0Hz,1H),8.76(d,J=2.0Hz,1H),8.18(d,J=2.0Hz,1H),7.94(d,J=9 .0Hz,1H),7.78(d,J=3.2Hz,1H),7.23(d,J=3.2Hz,1H),7.11(d,J=9.0Hz,1H),6.28(s,2H),5.64(s,2H).

[0930] MS(ESI):[M+H + ]316.31

[0931] Compound 55

[0932] 1 H NMR (400MHz, Methanol-d4) δ8.11(d,J=1.2Hz,1H),7.45(d,J=3.2Hz,1H),6.96(dd,J=3.2,0 .8Hz,1H),6.27(d,J=1.0Hz,1H),5.31(d,J=1.0Hz,1H),5.14(t,J=1.6Hz,2H),3.79(s,3H).

[0933] MS(ESI):[M+H + ]376.22

[0934] Compound 56

[0935] 1 H NMR(400MHz, Methanol-d4)δ7.60(d,J=3.2Hz,1H),7.41(t,J=3.2Hz,1H),7.19-7.14(m,2H),7 .04(dd,J=8.8,3.2Hz,2H),6.95(t,J=3.2Hz,1H),5.44(d,J=3.2Hz,2H),2.52(d,J=3.2Hz,3H).

[0936] MS(ESI):[M+H + ]322.34

[0937] Compound 57

[0938] 1H NMR (400MHz, DMSO-d6) δ8.16(d,J=5.2Hz,1H),7.71(d,J=9.0Hz,1H),7.66(d,J=3.2Hz,1H),7.18(d,J=3.2Hz ,1H),7.05(d,J=9.0Hz,1H),7.00-6.98(m,1H),6.84(d,J=1.5Hz,1H),6.79(s,2H),5.80(s,2H),5.64(s,2H).

[0939] MS(ESI):[M+H + ]309.36

[0940] Compound 58

[0941] 1 H NMR (400MHz, DMSO-d6) δ7.91-7.79(m,3H),7.63(d,J=3.2Hz,1H),7.11(d,J=3.2Hz,1H),7.05(d,J=8.8Hz,1H),6.74(s,2H),5.77(s,2H),5.51(s,2H).

[0942] MS(ESI):[M+H + ]321.38

[0943] Compound 59

[0944] 1 H NMR (400MHz, DMSO-d6) δ8.85(d,J=2.4Hz,1H),8.01(dd,J=8.4,2.4Hz,1H),7.78(d,J=9.2Hz,1H),7.74-7.63(m,3H),7.48( t,J=7.2Hz,2H),7.41(t,J=7.2Hz,1H),7.15(d,J=3.2Hz,1H),7.05(d,J=8.4Hz,2H),6.82(s,2H),5.83(s,2H),5.65(s,2H).

[0945] MS(ESI):[M+H + ]367.41

[0946] Compound 60

[0947] 1H NMR (400MHz, DMSO-d6) δ8.42(d,J=2.4Hz,1H),7.77(d,J=8.8Hz,1H),7.68-7.54(m,2H),7.13(d,J=3.2Hz,1H),7.04(d,J=8.8Hz, 1H),6.92(d,J=8.0Hz,1H),6.87(s,2H),5.91(s,2H),5.55(s,2H),2.88(m,1H),1.17(d,J=6.8Hz,6H).

[0948] MS(ESI):[M+H + ]333.40

[0949] Compound 61

[0950] 1 H NMR (400MHz, DMSO-d6) δ7.92-7.82(m,2H),7.62(d,J=3.2Hz,1H),7.13(d,J=3.2Hz,1H),7.07(d,J=9.2Hz,1H),6.83(s,2H),5.87(s,2H),5.71(s,2H).

[0951] MS(ESI):[M+H + ]365.33

[0952] Compound 62

[0953] 1 H NMR (400MHz, DMSO-d6) δ8.63(dt,J=4.8,1.6Hz,1H),8.06-7.98(m,2H),7.94-7.81(m,2H),7.78(d,J=9.0Hz,1H),7.69(d,J =3.2Hz,1H),7.35-7.25(m,3H),7.15(d,J=3.2Hz,1H),7.05(d,J=9.0Hz,1H),6.85(s,2H),5.93-5.80(m,2H),5.58(s,2H).

[0954] MS(ESI):[M+H + ]367.41

[0955] Compound 63

[0956] 1H NMR(400MHz, DMSO-d6)δ7.71(d,J=8.8Hz,1H),7.45(d,J=3.2Hz,1H),7.14-6.99(m, 2H),6.66(s,2H),6.15(s,1H),5.67(s,2H),5.24(s,1H),5.14(s,2H),3.73(s,3H).

[0957] MS(ESI):[M+H + ]298.11

[0958] Compound 64

[0959] 1 H NMR (400MHz, DMSO-d6) δ8.47-8.25(m,1H),7.91-7.55(m,2H),7.01(m,5H),6.59(s,1H),6.04(s,2H),5.52(s,2H),3.73(s,3H).

[0960] MS(ESI):[M+H+]321.20

[0961] Compound 65

[0962] 1 H NMR (400MHz, DMSO-d6) δ7.83(s,2H),7.51-7.38(m,2H),7.19-7.11(m,4H),7.08(s,1H),6.55(s,2H),6.29(t,J=6.4Hz,1H),4.29(d,J=6.0Hz,2H).

[0963] MS(ESI):[M+H + ]284.30

[0964] Compound 66

[0965] 1 H NMR (400MHz, DMSO-d6) δ7.70(d,J=9.2Hz,1H),7.51(d,J=3.2Hz,1H),7.11(dd,J=8.0,2.8Hz,2H),7.05(d,J=9.2 Hz,1H),6.84(dd,J=8.4,2.4Hz,1H),6.76(s,2H),6.73(d,J=8.4Hz,1H),5.78(s,2H),5.50(s,2H),3.74(s,3H).

[0966] MS(ESI):[M+H + ]354.79

[0967] Compound 67

[0968] 1 H NMR (400MHz, DMSO-d6) δ7.74(dd,J=9.0,0.8Hz,1H),7.62(d,J=3.2Hz,1H),7.13-7.08(m,1H),7.04(d,J=9. 0Hz,1H),6.75(s,2H),6.38(t,J=2.4Hz,1H),6.34(d,J=2.4Hz,2H),5.76(s,2H),5.41(s,2H),3.67(s,6H).

[0969] MS(ESI):[M+H + ]350.34

[0970] Compound 68

[0971] 1 H NMR (400MHz, DMSO-d6) δ7.79(dd,J=9.0,0.8Hz,1H),7.69-7.50(m,2H),7.18-7.09(m,1H),7.05(d,J=8.8Hz,1H ),6.78(s,2H),6.69(dd,J=8.8,0.8Hz,1H),6.51(dd,J=7.2,0.8Hz,1H),5.80(s,2H),5.49(s,2H),3.82(s,3H).

[0972] MS(ESI):[M+H + ]321.37

[0973] Compound 69

[0974] 1 H NMR(400MHz, DMSO-d6)δ7.67(d,J=9.0Hz,1H),7.62-7.51(m,2H),7.33-7.13(m,2H),7. 04(d,J=9.0Hz,1H),6.76(s,2H),6.39(dd,J=7.6,1.2Hz,1H),5.76(s,2H),5.65(s,2H).

[0975] MS(ESI):[M+H + ]359.21

[0976] Compound 70

[0977] 1 H NMR (400MHz, DMSO-d6) δ7.78(d,J=8.8Hz,1H),7.62(d,J=3.0Hz,1H),7.08(d,J=3.0Hz,1H),7.0 3(d,J=8.8Hz,1H),6.88-6.79(m,2H),6.76-6.73(m,1H),5.96(s,2H),5.76(s,2H),5.38(s,2H).

[0978] MS(ESI):[M+H + ]334.36

[0979] Compound 71

[0980] 1 H NMR (400MHz, DMSO-d6) δ7.71(d,J=8.8Hz,1H),7.55(d,J=3.2Hz,1H),7.43(dd,J=8.8,2.4Hz,1H),7.10(d,J =3.2Hz,1H),7.07-7.01(m,2H),6.79(d,J=2.4Hz,1H),6.73(s,2H),5.75(s,2H),5.42(s,2H),3.87(s,3H).

[0981] MS(ESI):[M+H+]398.24

[0982] Compound 72

[0983] 1 H NMR (400MHz, DMSO-d6) δ7.83(d,J=9.2Hz,1H),7.64(d,J=3.2Hz,1H),7.09(d,J=3.2Hz,1H),7.04 (d,J=9.2Hz,1H),6.74(s,2H),6.61(s,2H),5.76(s,2H),5.38(s,2H),3.68(s,6H),3.59(s,3H).

[0984] MS(ESI):[M+H+]398.24

[0985] Biological Examples

[0986] THP-1 / U937 cells in the exponential growth phase (survival rate of more than 98%) were collected and counted. A portion of the cell suspension was added with 20 ng / mL PMA, resuspended in complete medium, and plated onto a sterile 96-well culture plate. Each well contained 100 μL of cell suspension at a cell density of 5 × 10 5 / mL. After 48 hours of PMA-induced cell differentiation, discard the old medium and add 100 μL of complete medium to each well of cells and continue incubation for a further 24 hours. After 24 hours, discard the old medium and add 100 μL of complete medium containing Mycobacterium tuberculosis to each well of cells and continue incubation for a further 4 hours. After 4 hours, discard the old medium, wash the cells three times with PBS, and then add 100 μL of complete medium containing 50 μM drug to each well of cells and continue incubation for a further 48 hours. After 48 hours, discard the old medium and add 100 μL of complete medium containing 20 ng / mL tetracycline inducer to the 96-well plate. After another 24 hours of incubation, centrifuge the cells in the 96-well plate, discard the supernatant, wash twice with PBS, and add 100 μL of PBS. Finally, measure the absorbance at wavelengths of 479 / 520 nm and 555 / 591 nm in a microplate reader.

[0987] MT WT The strain refers to the Mycobacterium tuberculosis H37Rv standard strain; MT 26-2 The strain came from Shenzhen Third People's Hospital. It was a clinical isolate from a pulmonary tuberculosis patient in the hospital and was dual-resistant to isoniazid and rifampicin. The hospital used the C26 (clinical) strain as its identifier.

[0988] In this disclosure, relational terms such as first and second, etc. are used merely to distinguish one entity or operation from another entity or operation, but do not necessarily require or imply any actual relationship or order between these entities or operations.

[0989] It will be appreciated from the foregoing that, although specific embodiments of the present disclosure have been described for illustrative purposes, various modifications or variations may be made by those skilled in the art without departing from the spirit and scope of the present disclosure. Such modifications or variations are intended to fall within the scope of the appended claims of the present disclosure.

Claims

1. A method for preventing or treating tuberculosis (TB), comprising administering to an individual in need thereof a preventive or therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; R3 is selected from an optionally substituted amino group; R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy; R6 is selected from a chemical bond or an optionally substituted alkylene group; R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and X is selected from CH or N.

2. The method of claim 1, wherein R1 and R2 are each independently selected from hydrogen, an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted cycloalkyl group.

3. The method of claim 1 or 2, wherein R1 and R2 are each independently selected from hydrogen or cyclopropyl.

4. The method according to any one of claims 1 to 3, wherein R3 is selected from unsubstituted amino or amino substituted by an optionally substituted alkyl group.

5. The method according to any one of claims 1 to 4, wherein R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino or optionally substituted aryl-substituted alkyl-substituted amino.

6. The method of any one of claims 1 to 5, wherein R is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

7. The method according to any one of claims 1 to 6, wherein R3 is selected from amino, hydroxyethylamino, iodobenzylamino, vinylbenzylamino, ethynylbenzylamino or triethylsilylethynylbenzylamino.

8. The method of any one of claims 1 to 7, wherein R3 is selected from -NH2, 9. The method of any one of claims 1 to 8, wherein R4 is selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, halogen-substituted aryl, alkoxy-substituted aryl, or unsubstituted heteroaryl.

10. The method of any one of claims 1 to 9, wherein R4 is selected from hydrogen, bromo, methyl, cyclopropyl, fluoro-substituted phenyl, methoxy-substituted phenyl or pyridyl.

11. The method of any one of claims 1 to 10, wherein R4 is selected from the group consisting of H, Br, -CH3, 12. The method of any one of claims 1 to 11, wherein R5 is selected from hydrogen or unsubstituted alkyl.

13. The method of any one of claims 1 to 12, wherein R5 is selected from hydrogen or methyl.

14. The method of any one of claims 1 to 13, wherein R6 is selected from a chemical bond, an unsubstituted alkylene group, or an optionally substituted alkylene group.

15. The method of any one of claims 1 to 14, wherein R6 is selected from a chemical bond, -CH2-, -CH2CH2-, or -CH(CH3)-.

16. The method of any one of claims 1 to 15, wherein R is selected from optionally substituted aryl-substituted alkyl, alkenyl, optionally substituted aryl-substituted alkenyl, optionally substituted aryl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted aryl-substituted aryl, optionally substituted heteroaryl-substituted aryl, optionally substituted aryloxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted aryl-substituted heteroaryl.

17. The method of any one of claims 1 to 16, wherein R is selected from the group consisting of methyl substituted by fluorophenyl, vinyl, vinyl substituted by methoxycarbonyl, propenyl substituted by methoxycarbonyl, propenyl substituted by phenyl, propynyl substituted by phenyl, cyclopentyl, fluoro substituted phenyl, chloro substituted phenyl, bromo substituted phenyl, nitro substituted phenyl, ethyl substituted phenyl, isopropyl substituted phenyl, vinyl substituted phenyl, ethynyl substituted phenyl, cyclopropylethynyl substituted phenyl, triethylsilylethynyl substituted phenyl, phenylethynyl substituted phenyl, propynyl substituted phenyl, aminopropynyl substituted phenyl, dimethylamino substituted phenyl, methylbutynyl-substituted phenyl, tert-butoxycarbonylaminopropynyl-substituted phenyl, methoxy-substituted phenyl, dimethoxy-substituted phenyl, trimethoxy-substituted phenyl, phenoxy-substituted phenyl, boronic acid-substituted phenyl, biphenyl, pyridyl-substituted phenyl, naphthyl, bromo-substituted naphthyl, methyl-substituted naphthyl, isoquinolyl, cyano-substituted thienyl, fluorine-substituted pyridyl, isopropyl-substituted pyridyl, trifluoromethyl-substituted pyridyl, methoxy-substituted pyridyl, cyano-substituted pyridyl, phenyl-substituted pyridyl, trifluoromethyl-substituted thiazolyl or benzo[d][1,3]dioxolyl.

18. The method of any one of claims 1 to 17, wherein R7 is selected from the group consisting of vinyl, 19. The method according to any one of claims 1 to 18, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from: 7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 2-((7-([1,1'-biphenyl]-4-ylmethyl)-3-amino-7H-pyrrolo[3,2-f]quinazolin-1-yl)amino)ethan-1-ol; 7-(3-phenylpropyl-2-yn-1-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-cinnamyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3-phenoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-ethynylbenzyl)-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; (Z)-2-cyano-1-(1-(4-ethynylbenzyl)-2-methyl-1H-benzimidazol-5-yl)guanidine; 7-(4-isopropylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Cyclopentylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,4-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,5-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; tert-Butyl (3-(4-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)prop-2-yn-1-yl)carbamate; N 3 -cyclopropyl-7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-aminopropyl-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Naphth-2-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1 -(4-iodobenzyl)-7-(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-ethynylbenzyl)-N 1 -(4-iodobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Ethylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile; 7-(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-nitrobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-allyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(1-(4-fluorophenyl)ethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Naphthalen-1-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Quinolin-8-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorophenylethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-5-(4-methoxyphenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-methylnaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-5-(pyridin-3-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-bromonaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-fluoropyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-Bromo-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-Bromo-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-fluoropyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-cyclopropyl-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-(trifluoromethyl)pyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; (4-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)boronic acid; 7-(4-Fluorobenzyl)-5-(4-fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)nicotinonitrile; Methyl 2-((1,3-diamino-5-bromo-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate; 7-(4-Fluorobenzyl)-5-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((2-fluoropyridin-4-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile; 7-((5-phenylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((5-isopropylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(2-(trifluoromethyl)thiazol-5-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(pyridin-2-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; Methyl 2-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate; 7-(4-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 7 -(4-fluorobenzyl)quinazoline-2,4,7-triamine; 7-(2-chloro-4-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,5-dimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(6-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(2,3-Dichlorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Benzo[d][1,3]dioxol-5-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(5-bromo-2-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; and 7-(3,4,5-Trimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

20. The method of any one of claims 1 to 19, further comprising administering to the individual other drugs for preventing or treating tuberculosis.

21. The method of claim 20, wherein the other drugs for preventing or treating tuberculosis are selected from isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, pyrazinamide, sodium para-aminosalicylate, rifapentine and prothionamide.

22. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use in preventing or treating tuberculosis (TB). in R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; R3 is selected from an optionally substituted amino group; R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy; R6 is selected from a chemical bond or an optionally substituted alkylene group; R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and X is selected from CH or N.

23. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 22, wherein R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy or optionally substituted cycloalkyl.

24. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 22 or 23, wherein R1 and R2 are each independently selected from hydrogen or cyclopropyl.

25. The compound of general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 24, wherein R3 is selected from unsubstituted amino or amino substituted by an optionally substituted alkyl group.

26. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 25, wherein R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino or optionally substituted aryl-substituted alkyl-substituted amino.

27. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 26, wherein R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino or optionally substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

28. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 27, wherein R3 is selected from amino, hydroxyethylamino, iodobenzylamino, vinylbenzylamino, ethynylbenzylamino or triethylsilylethynylbenzylamino.

29. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 28, wherein R3 is selected from -NH2, 30. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 29, wherein R4 is selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, halogen-substituted aryl, alkoxy-substituted aryl or unsubstituted heteroaryl.

31. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 30, wherein R4 is selected from hydrogen, bromo, methyl, cyclopropyl, fluoro-substituted phenyl, methoxy-substituted phenyl or pyridyl.

32. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 31, wherein R4 is selected from H, Br, -CH3, 33. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 32, wherein R5 is selected from hydrogen or unsubstituted alkyl.

34. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 33, wherein R5 is selected from hydrogen or methyl.

35. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 34, wherein R6 is selected from a chemical bond, an unsubstituted alkylene group or an alkylene group substituted by an optionally substituted alkyl group.

36. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 35, wherein R6 is selected from a chemical bond, -CH2-, -CH2CH2- or -CH(CH3)-.

37. A compound of formula (I) as claimed in any one of claims 22 to 36, or a pharmaceutically acceptable salt thereof, wherein R is selected from optionally substituted aryl-substituted alkyl, alkenyl, optionally substituted aryl-substituted alkenyl, optionally substituted aryl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, borate-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted aryl-substituted aryl, optionally substituted heteroaryl-substituted aryl, optionally substituted aryloxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl or optionally substituted aryl-substituted heteroaryl.

38. A compound of formula (I) as claimed in any one of claims 22 to 37, or a pharmaceutically acceptable salt thereof, wherein R7 is selected from methyl substituted by fluorophenyl, vinyl, vinyl substituted by methoxycarbonyl, propenyl substituted by methoxycarbonyl, propenyl substituted by phenyl, propynyl substituted by phenyl, cyclopentyl, fluoro substituted phenyl, chloro substituted phenyl, bromo substituted phenyl, nitro substituted phenyl, ethyl substituted phenyl, isopropyl substituted phenyl, vinyl substituted phenyl, ethynyl substituted phenyl, cyclopropylethynyl substituted phenyl, triethylsilylethynyl substituted phenyl, phenylethynyl substituted phenyl, propynyl substituted phenyl, aminopropynyl substituted phenyl phenyl, dimethylaminopropynyl-substituted phenyl, methylbutynyl-substituted phenyl, tert-butoxycarbonylaminopropynyl-substituted phenyl, methoxy-substituted phenyl, dimethoxy-substituted phenyl, trimethoxy-substituted phenyl, phenoxy-substituted phenyl, boronic acid-substituted phenyl, biphenyl, pyridyl-substituted phenyl, naphthyl, bromo-substituted naphthyl, methyl-substituted naphthyl, isoquinolyl, cyano-substituted thienyl, fluorine-substituted pyridyl, isopropyl-substituted pyridyl, trifluoromethyl-substituted pyridyl, methoxy-substituted pyridyl, cyano-substituted pyridyl, phenyl-substituted pyridyl, trifluoromethyl-substituted thiazolyl or benzo[d][1,3]dioxolyl.

39. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 38, wherein R7 is selected from vinyl, 40. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 22 to 39, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from: 7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 2-((7-([1,1'-biphenyl]-4-ylmethyl)-3-amino-7H-pyrrolo[3,2-f]quinazolin-1-yl)amino)ethan-1-ol; 7-(3-phenylpropyl-2-yn-1-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-cinnamyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3-phenoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-ethynylbenzyl)-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; (Z)-2-cyano-1-(1-(4-ethynylbenzyl)-2-methyl-1H-benzimidazol-5-yl)guanidine; 7-(4-isopropylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Cyclopentylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,4-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,5-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; tert-Butyl (3-(4-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)prop-2-yn-1-yl)carbamate; N 3 -cyclopropyl-7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-aminopropyl-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Naphth-2-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1 -(4-iodobenzyl)-7-(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-ethynylbenzyl)-N 1 -(4-iodobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Ethylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile; 7-(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-nitrobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-allyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(1-(4-fluorophenyl)ethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Naphthalen-1-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Quinolin-8-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorophenylethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-5-(4-methoxyphenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-methylnaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-5-(pyridin-3-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-bromonaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-fluoropyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-Bromo-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-Bromo-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-fluoropyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-cyclopropyl-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-(trifluoromethyl)pyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; (4-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)boronic acid; 7-(4-Fluorobenzyl)-5-(4-fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)nicotinonitrile; Methyl 2-((1,3-diamino-5-bromo-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate; 7-(4-Fluorobenzyl)-5-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((2-fluoropyridin-4-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile; 7-((5-phenylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((5-isopropylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(2-(trifluoromethyl)thiazol-5-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(pyridin-2-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; Methyl 2-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate; 7-(4-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 7 -(4-fluorobenzyl)quinazoline-2,4,7-triamine; 7-(2-chloro-4-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,5-dimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(6-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(2,3-Dichlorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Benzo[d][1,3]dioxol-5-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(5-bromo-2-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; and 7-(3,4,5-Trimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

41. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing or treating tuberculosis (TB), in R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; R3 is selected from an optionally substituted amino group; R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclic, optionally substituted aryl or optionally substituted heteroaryl; R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy; R6 is selected from a chemical bond or an optionally substituted alkylene group; R7 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; and X is selected from CH or N.

42. The method of claim 41, wherein R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy or optionally substituted cycloalkyl.

43. The method of claim 41 or 42, wherein R1 and R2 are each independently selected from hydrogen or cyclopropyl.

44. The method of any one of claims 41 to 43, wherein R3 is selected from unsubstituted amino or optionally substituted alkyl-substituted amino.

45. The use according to any one of claims 41 to 44, wherein R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino or optionally substituted aryl-substituted alkyl-substituted amino.

46. ​​The method of any one of claims 41 to 45, wherein R is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

47. The method of any one of claims 41 to 46, wherein R3 is selected from amino, hydroxyethylamino, iodobenzylamino, vinylbenzylamino, ethynylbenzylamino or triethylsilylethynylbenzylamino.

48. The use according to any one of claims 41 to 47, wherein R3 is selected from -NH2, 49. The method of any one of claims 41 to 48, wherein R4 is selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, halogen-substituted aryl, alkoxy-substituted aryl, or unsubstituted heteroaryl.

50. The method of any one of claims 41 to 49, wherein R4 is selected from hydrogen, bromo, methyl, cyclopropyl, fluoro-substituted phenyl, methoxy-substituted phenyl or pyridyl.

51. The use of any one of claims 41 to 50, wherein R4 is selected from H, Br, -CH3, 52. The use according to any one of claims 41 to 51, wherein R5 is selected from hydrogen or unsubstituted alkyl.

53. The use according to any one of claims 41 to 52, wherein R5 is selected from hydrogen or methyl.

54. The method of any one of claims 41 to 53, wherein R6 is selected from a chemical bond, an unsubstituted alkylene group or an optionally substituted alkylene group.

55. The use according to any one of claims 41 to 54, wherein R6 is selected from a chemical bond, -CH2-, -CH2CH2- or -CH(CH3)-.

56. The method of claim 41, wherein R is selected from the group consisting of alkyl, alkenyl, alkenyl, alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen, nitro, boric acid, aryl, aryl, alkyl, alkenyl, alkynyl, aryl, alkoxy, aryl, aryl, heteroaryl, aryl, aryl, aryl, aryl, substituted hetero ...

57. The use of any one of claims 41 to 56, wherein R is selected from the group consisting of methyl substituted by fluorophenyl, vinyl, vinyl substituted by methoxycarbonyl, propenyl substituted by methoxycarbonyl, propenyl substituted by phenyl, propynyl substituted by phenyl, cyclopentyl, fluoro substituted phenyl, chloro substituted phenyl, bromo substituted phenyl, nitro substituted phenyl, ethyl substituted phenyl, isopropyl substituted phenyl, vinyl substituted phenyl, ethynyl substituted phenyl, cyclopropylethynyl substituted phenyl, triethylsilylethynyl substituted phenyl, phenylethynyl substituted phenyl, propynyl substituted phenyl, aminopropynyl substituted phenyl, dimethyl aminopropynyl-substituted phenyl, methylbutynyl-substituted phenyl, tert-butoxycarbonylaminopropynyl-substituted phenyl, methoxy-substituted phenyl, dimethoxy-substituted phenyl, trimethoxy-substituted phenyl, phenoxy-substituted phenyl, boronic acid-substituted phenyl, biphenyl, pyridyl-substituted phenyl, naphthyl, bromo-substituted naphthyl, methyl-substituted naphthyl, isoquinolyl, cyano-substituted thienyl, fluorine-substituted pyridyl, isopropyl-substituted pyridyl, trifluoromethyl-substituted pyridyl, methoxy-substituted pyridyl, cyano-substituted pyridyl, phenyl-substituted pyridyl, trifluoromethyl-substituted thiazolyl or benzo[d][1,3]dioxolyl.

58. The use of any one of claims 41 to 57, wherein R7 is selected from the group consisting of vinyl, 59. The use according to any one of claims 41 to 58, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from: 7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 2-((7-([1,1'-biphenyl]-4-ylmethyl)-3-amino-7H-pyrrolo[3,2-f]quinazolin-1-yl)amino)ethan-1-ol; 7-(3-phenylpropyl-2-yn-1-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-cinnamyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3-phenoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-ethynylbenzyl)-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; (Z)-2-cyano-1-(1-(4-ethynylbenzyl)-2-methyl-1H-benzimidazol-5-yl)guanidine; 7-(4-isopropylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Cyclopentylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,4-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,5-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; tert-Butyl (3-(4-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)prop-2-yn-1-yl)carbamate; N 3 -cyclopropyl-7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-aminopropyl-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Naphth-2-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1 -(4-iodobenzyl)-7-(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-ethynylbenzyl)-N 1 -(4-iodobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Ethylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile; 7-(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-nitrobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-allyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(1-(4-fluorophenyl)ethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Naphthalen-1-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Quinolin-8-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorophenylethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-5-(4-methoxyphenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-methylnaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-5-(pyridin-3-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-bromonaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-fluoropyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-Bromo-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-Bromo-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-fluoropyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-cyclopropyl-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-(trifluoromethyl)pyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; (4-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)boronic acid; 7-(4-Fluorobenzyl)-5-(4-fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)nicotinonitrile; Methyl 2-((1,3-diamino-5-bromo-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate; 7-(4-Fluorobenzyl)-5-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((2-fluoropyridin-4-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile; 7-((5-phenylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((5-isopropylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(2-(trifluoromethyl)thiazol-5-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(pyridin-2-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; Methyl 2-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate; 7-(4-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 7 -(4-fluorobenzyl)quinazoline-2,4,7-triamine; 7-(2-chloro-4-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,5-dimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(6-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(2,3-Dichlorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Benzo[d][1,3]dioxol-5-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(5-bromo-2-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; and 7-(3,4,5-Trimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

60. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in preventing or treating tuberculosis (TB). in R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; R3 is selected from an optionally substituted amino group; R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy; R6 is selected from a chemical bond or an optionally substituted alkylene group; R7 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclic, aryl or optionally substituted heteroaryl; and X is selected from CH or N.

61. The method of claim 60, wherein R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy or optionally substituted cycloalkyl.

62. The method of claim 60 or 61, wherein R1 and R2 are each independently selected from hydrogen or cyclopropyl.

63. The use according to any one of claims 60 to 62, wherein R3 is selected from unsubstituted amino or optionally substituted alkyl-substituted amino.

64. The use according to any one of claims 60 to 63, wherein R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino or optionally substituted aryl-substituted alkyl-substituted amino.

65. The method of any one of claims 60 to 64, wherein R is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

66. The method of any one of claims 60 to 65, wherein R3 is selected from amino, hydroxyethylamino, iodobenzylamino, vinylbenzylamino, ethynylbenzylamino or triethylsilylethynylbenzylamino.

67. The use according to any one of claims 60 to 66, wherein R3 is selected from -NH2, 68. The use of any one of claims 60 to 67, wherein R4 is selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, halogen-substituted aryl, alkoxy-substituted aryl, or unsubstituted heteroaryl.

69. The method of any one of claims 60 to 68, wherein R4 is selected from hydrogen, bromo, methyl, cyclopropyl, fluoro-substituted phenyl, methoxy-substituted phenyl or pyridyl.

70. The use of any one of claims 60 to 69, wherein R4 is selected from H, Br, -CH3, 71. The use of any one of claims 60 to 70, wherein R5 is selected from hydrogen or unsubstituted alkyl.

72. The use according to any one of claims 60 to 71, wherein R5 is selected from hydrogen or methyl.

73. The use according to any one of claims 60 to 72, wherein R6 is selected from a chemical bond, an unsubstituted alkylene group or an optionally substituted alkylene group.

74. The use of any one of claims 60 to 73, wherein R6 is selected from a chemical bond, -CH2-, -CH2CH2-, or -CH(CH3)-.

75. The method of any one of claims 60 to 74, wherein R is selected from the group consisting of alkyl, alkenyl, alkenyl, alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boric acid-substituted aryl, aryl, alkyl, alkenyl, alkynyl, aryl, alkoxy, aryl, aryl, heteroaryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, aryl, halogen-substituted aryl, cyano-substituted aryl, heteroaryl, alkyl, alkoxy, or aryl.

76. The use of any one of claims 60 to 75, wherein R is selected from the group consisting of methyl substituted by fluorophenyl, vinyl, vinyl substituted by methoxycarbonyl, propenyl substituted by methoxycarbonyl, propenyl substituted by phenyl, propynyl substituted by phenyl, cyclopentyl, fluoro substituted phenyl, chloro substituted phenyl, bromo substituted phenyl, nitro substituted phenyl, ethyl substituted phenyl, isopropyl substituted phenyl, vinyl substituted phenyl, ethynyl substituted phenyl, cyclopropylethynyl substituted phenyl, triethylsilylethynyl substituted phenyl, phenylethynyl substituted phenyl, propynyl substituted phenyl, aminopropynyl substituted phenyl, dimethyl aminopropynyl-substituted phenyl, methylbutynyl-substituted phenyl, tert-butoxycarbonylaminopropynyl-substituted phenyl, methoxy-substituted phenyl, dimethoxy-substituted phenyl, trimethoxy-substituted phenyl, phenoxy-substituted phenyl, boronic acid-substituted phenyl, biphenyl, pyridyl-substituted phenyl, naphthyl, bromo-substituted naphthyl, methyl-substituted naphthyl, isoquinolyl, cyano-substituted thienyl, fluorine-substituted pyridyl, isopropyl-substituted pyridyl, trifluoromethyl-substituted pyridyl, methoxy-substituted pyridyl, cyano-substituted pyridyl, phenyl-substituted pyridyl, trifluoromethyl-substituted thiazolyl or benzo[d][1,3]dioxolyl.

77. The use of any one of claims 60 to 76, wherein R7 is selected from vinyl, 78. The use according to any one of claims 60 to 77, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from: 7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 2-((7-([1,1'-biphenyl]-4-ylmethyl)-3-amino-7H-pyrrolo[3,2-f]quinazolin-1-yl)amino)ethan-1-ol; 7-(3-phenylpropyl-2-yn-1-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-cinnamyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3-phenoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-ethynylbenzyl)-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; (Z)-2-cyano-1-(1-(4-ethynylbenzyl)-2-methyl-1H-benzimidazol-5-yl)guanidine; 7-(4-isopropylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Cyclopentylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,4-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,5-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; tert-Butyl (3-(4-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)prop-2-yn-1-yl)carbamate; N 3 -cyclopropyl-7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-aminopropyl-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Naphth-2-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1 -(4-iodobenzyl)-7-(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-ethynylbenzyl)-N 1 -(4-iodobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Ethylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile; 7-(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-nitrobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-allyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(1-(4-fluorophenyl)ethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Naphthalen-1-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Quinolin-8-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorophenylethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-5-(4-methoxyphenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-methylnaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-5-(pyridin-3-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-bromonaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-fluoropyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-Bromo-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-Bromo-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-fluoropyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-cyclopropyl-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-(trifluoromethyl)pyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; (4-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)boronic acid; 7-(4-Fluorobenzyl)-5-(4-fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)nicotinonitrile; Methyl 2-((1,3-diamino-5-bromo-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate; 7-(4-Fluorobenzyl)-5-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((2-fluoropyridin-4-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile; 7-((5-phenylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((5-isopropylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(2-(trifluoromethyl)thiazol-5-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(pyridin-2-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; Methyl 2-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate; 7-(4-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 7 -(4-fluorobenzyl)quinazoline-2,4,7-triamine; 7-(2-chloro-4-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,5-dimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(6-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(2,3-Dichlorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Benzo[d][1,3]dioxol-5-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(5-bromo-2-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; and 7-(3,4,5-Trimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

79. A pharmaceutical composition for preventing or treating tuberculosis (TB), comprising a preventive or therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. in R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; R3 is selected from an optionally substituted amino group; R4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl or optionally substituted heteroaryl; R5 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy; R6 is selected from a chemical bond or an optionally substituted alkylene group; R7 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, an optionally substituted alkoxy group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group; and X is selected from CH or N.

80. The pharmaceutical composition of claim 79, wherein R1 and R2 are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted cycloalkyl.

81. The pharmaceutical composition of claim 79 or 80, wherein R1 and R2 are each independently selected from hydrogen or cyclopropyl.

82. The pharmaceutical composition of any one of claims 79 to 81, wherein R3 is selected from unsubstituted amino or optionally substituted alkyl-substituted amino.

83. The pharmaceutical composition of any one of claims 79 to 82, wherein R3 is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, or optionally substituted aryl-substituted alkyl-substituted amino.

84. The pharmaceutical composition of any one of claims 79 to 83, wherein R is selected from unsubstituted amino, hydroxy-substituted alkyl-substituted amino, halogen-substituted aryl-substituted alkyl-substituted amino, optionally substituted alkenyl-substituted aryl-substituted alkyl-substituted amino, or optionally substituted alkynyl-substituted aryl-substituted alkyl-substituted amino.

85. The pharmaceutical composition of any one of claims 79 to 84, wherein R3 is selected from amino, hydroxyethylamino, iodobenzylamino, vinylbenzylamino, ethynylbenzylamino, or triethylsilylethynylbenzylamino.

86. The pharmaceutical composition of any one of claims 79 to 85, wherein R3 is selected from -NH2, 87. The pharmaceutical composition of any one of claims 79 to 86, wherein R4 is selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, halogen-substituted aryl, alkoxy-substituted aryl, or unsubstituted heteroaryl.

88. The pharmaceutical composition of any one of claims 79 to 87, wherein R4 is selected from hydrogen, bromo, methyl, cyclopropyl, fluoro-substituted phenyl, methoxy-substituted phenyl, or pyridyl.

89. The pharmaceutical composition of any one of claims 79 to 88, wherein R4 is selected from H, Br, -CH3, 90. The pharmaceutical composition of any one of claims 79 to 89, wherein R5 is selected from hydrogen or unsubstituted alkyl.

91. The pharmaceutical composition of any one of claims 79 to 90, wherein R5 is selected from hydrogen or methyl.

92. The pharmaceutical composition of any one of claims 79 to 91, wherein R6 is selected from a chemical bond, an unsubstituted alkylene group, or an optionally substituted alkylene group.

93. The pharmaceutical composition of any one of claims 79 to 92, wherein R6 is selected from a chemical bond, -CH2-, -CH2CH2-, or -CH(CH3)-.

94. The pharmaceutical composition of any one of claims 79 to 93, wherein R is selected from optionally substituted aryl-substituted alkyl, alkenyl, optionally substituted aryl-substituted alkenyl, optionally substituted aryl-substituted alkynyl, unsubstituted cycloalkyl, unsubstituted aryl, halogen-substituted aryl, nitro-substituted aryl, boronic acid-substituted aryl, optionally substituted alkyl-substituted aryl, optionally substituted alkenyl-substituted aryl, optionally substituted alkynyl-substituted aryl, optionally substituted alkoxy-substituted aryl, optionally substituted aryl-substituted aryl, optionally substituted heteroaryl-substituted aryl, optionally substituted aryloxy-substituted aryl, unsubstituted heteroaryl, halogen-substituted heteroaryl, cyano-substituted heteroaryl, optionally substituted alkyl-substituted heteroaryl, optionally substituted alkoxy-substituted heteroaryl, or optionally substituted aryl-substituted heteroaryl.

95. The pharmaceutical composition of any one of claims 79 to 94, wherein R is selected from the group consisting of methyl substituted by fluorophenyl, vinyl, methoxycarbonyl substituted vinyl, methoxycarbonyl substituted propenyl, phenyl substituted propenyl, phenyl substituted propynyl, cyclopentyl, fluoro substituted phenyl, chloro substituted phenyl, bromo substituted phenyl, nitro substituted phenyl, ethyl substituted phenyl, isopropyl substituted phenyl, vinyl substituted phenyl, ethynyl substituted phenyl, cyclopropylethynyl substituted phenyl, triethylsilylethynyl substituted phenyl, phenylethynyl substituted phenyl, propynyl substituted phenyl, aminopropynyl substituted phenyl, dimethyl substituted phenyl, methylbutynyl-substituted phenyl, tert-butoxycarbonylaminopropynyl-substituted phenyl, methoxy-substituted phenyl, dimethoxy-substituted phenyl, trimethoxy-substituted phenyl, phenoxy-substituted phenyl, boronic acid-substituted phenyl, biphenyl, pyridyl-substituted phenyl, naphthyl, bromo-substituted naphthyl, methyl-substituted naphthyl, isoquinolyl, cyano-substituted thienyl, fluorine-substituted pyridyl, isopropyl-substituted pyridyl, trifluoromethyl-substituted pyridyl, methoxy-substituted pyridyl, cyano-substituted pyridyl, phenyl-substituted pyridyl, trifluoromethyl-substituted thiazolyl or benzo[d][1,3]dioxolyl.

96. The pharmaceutical composition of any one of claims 79 to 95, wherein R7 is selected from the group consisting of vinyl, 97. The pharmaceutical composition of any one of claims 79 to 96, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from: 7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 2-((7-([1,1'-biphenyl]-4-ylmethyl)-3-amino-7H-pyrrolo[3,2-f]quinazolin-1-yl)amino)ethan-1-ol; 7-(3-phenylpropyl-2-yn-1-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-cinnamyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3-phenoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-ethynylbenzyl)-8-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; (Z)-2-cyano-1-(1-(4-ethynylbenzyl)-2-methyl-1H-benzimidazol-5-yl)guanidine; 7-(4-isopropylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Cyclopentylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3-Fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,4-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,5-difluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; tert-Butyl (3-(4-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)prop-2-yn-1-yl)carbamate; N 3 -cyclopropyl-7-(4-(3-methylbut-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 3 -cyclopropyl-7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(cyclopropylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(phenylethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(3-aminopropyl-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(prop-1-yn-1-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Naphth-2-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1 -(4-iodobenzyl)-7-(4-(triethylsilyl)ethynyl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-ethynylbenzyl)-N 1 -(4-iodobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Ethylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile; 7-(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 1,7 -bis(4-vinylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-nitrobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-allyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(1-(4-fluorophenyl)ethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Naphthalen-1-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Quinolin-8-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorophenylethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-5-(4-methoxyphenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-methylnaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-Fluorobenzyl)-5-(pyridin-3-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-bromonaphthalen-1-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-fluoropyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-Bromo-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-Bromo-7-(4-ethynylbenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-fluoropyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-cyclopropyl-7-(4-fluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((6-(trifluoromethyl)pyridin-3-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; (4-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)phenyl)boronic acid; 7-(4-Fluorobenzyl)-5-(4-fluorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)nicotinonitrile; Methyl 2-((1,3-diamino-5-bromo-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate; 7-(4-Fluorobenzyl)-5-methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((2-fluoropyridin-4-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 5-((1,3-Diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)thiophene-2-carbonitrile; 7-((5-phenylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-((5-isopropylpyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(2-(trifluoromethyl)thiazol-5-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(4-(pyridin-2-yl)benzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; Methyl 2-((1,3-diamino-7H-pyrrolo[3,2-f]quinazolin-7-yl)methyl)acrylate; 7-(4-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; N 7 -(4-fluorobenzyl)quinazoline-2,4,7-triamine; 7-(2-chloro-4-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(3,5-dimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(6-methoxypyridin-2-yl)methyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(2,3-Dichlorophenyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(Benzo[d][1,3]dioxol-5-ylmethyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; 7-(5-bromo-2-methoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; and 7-(3,4,5-Trimethoxybenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.

Images